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Abstract
Investigating the Effect of Allostery on Downstream Biology of the
Epidermal Growth Factor Receptor
Deepto Mozumdar
2021

The Epidermal Growth Factor Receptor (EGFR) is a member of the receptor tyrosine
kinase (RTK) family of human proteins with a critical role in transducing diverse extracellular
chemical information to initiate multiple cellular signaling cascade in the cell that are essential
for normal cell development. Aberrant activation of this receptor via mutation or overexpression
misregulates this flow of information and is implicated in a multiple human carcinoma. Thus,
understanding the molecular mechanisms by which chemical information is encoded and
decoded in EGFR is imperative both from a basic cell biology and therapeutic standpoint.
In this thesis consisting of four chapters, I describe my graduate work studying the
structure of a portion of EGFR called the juxtamembrane segment (JM) and investigating its
role in modulating and controlling the downstream biology of the receptor.
Chapter 1: This chapter provides an introduction, overview and in-depth discussion of
the literature pertaining to the critical role of JM in modulating EGFR biology through its
manifold functions in kinase activation, allosterically encoding structural changes in the various
domains of EGFR, and its interactions with diverse intracellular components.
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Chapter 2: In this chapter I describe my work utilizing a chemical biology tool called
Bipartite Tetracysteine Display to study to the structure of the JM of a constitutively active
variant of EGFR, namely EGFRvIII that is implicated in most cases of Glioblastoma Multiforme.
Through my studies I illustrate how the assembly of unique structures within the JM segment
of this oncogenic receptor supports the constitutive activity of this protein.
Chapter 3: In this chapter I describe my work utilizing tools in chemical biology,
biochemistry and cell biology to demonstrate that the assembly of discrete coiled coil
structures within the JM segment of EGFR is necessary and sufficient for controlling the path
of endocytic trafficking of the receptor and its intracellular lifetime. Furthermore, I demonstrate
how the assembly of these discrete JM structures also predicts kinase-independent effects of
oncogenic EGFR mutations (implicated in Non-Small Cell Lung Cancer) and clinically relevant
tyrosine kinase inhibitors that promote efficient, lysosome-based EGFR degradation.
Chapter 4: This chapter describes preliminary experiments that were performed on two
projects that were initiated in the early and later parts of Ph.D. research. The first project seeks
to investigate the role of receptor multimerization on the JM structure of EGFR. The second
ongoing project seeks to investigate the effect of JM structure on the interactome of WT and
oncogenic EGFR using APEX2-based proximity labeling and mass spectrometry. For both
projects, I discuss my rationale, experimental design and preliminary results and provide my
thoughts for future directions.
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Chapter 1. The juxtamembrane region of the epidermal growth factor receptor is a
critical modulatory element of growth factor dependent signaling.
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Chapter 1. The juxtamembrane region of the epidermal growth factor receptor is a
critical modulatory element of growth factor dependent signaling.
1.1. Introduction
The epidermal growth factor receptor [1,2] (EGFR; also referred to as ErbB1 [3]/ HER) is a
member of the receptor tyrosine kinase (RTK) family of human proteins [4,5], and functions as a
conduit for the flow of information across the cell membrane [6]. In normal physiology,
chemical information encoded by multiple extracellular growth factors [3,7,8] is allosterically
communicated through EGFR into the cell interior, to effect diverse signaling outcomes that
support cell growth and survival [4,6]. Misregulation of this information flow via mutation or
overexpression of EGFR, is associated with multiple human cancers and disease pathologies
[9–11]. Given its critical role both from a physiological and therapeutic standpoint, it has been a
long standing goal to decipher the molecular mechanisms by which chemical information is
encoded and decoded in EGFR.
EGFR is a 1186 amino acid long transmembrane protein consisting of five connected domains/
segments, namely the extracellular domain (ECD), the transmembrane (TM) and juxtamembrane
(JM) domains, the tyrosine kinase (TK) domain and the C-terminal tail (C-tail) [6] (Figure 1.1.A).
Upon binding EGFR specific growth factors [7], the ECD undergoes conformational
rearrangements [12–14] that are propagated through the membrane-embedded TM helix
[15–17] and adjacent cytosolic JM [17–21] region to induce assembly of the intracellular kinase
domain into a catalytically competent asymmetric dimer conformation [22,18,19] (Figure 1.1.B).
Thereafter, the catalytically active kinase auto-phosphorylates the C-tail at multiple tyrosine
residues [3,4,6] and these phosphorylated tyrosines recruit diverse adaptor proteins to initiate
multiple cellular signaling cascades in the cell [3,4,6] (Figure 1.1B,C). Our current
2

understanding of how the different parts of EGFR function in the mechanism of growth factor
induced receptor activation, is based on high resolution structural studies of the isolated EGFR
domains (ECD [12–14,23], TM [15,24], JM [15,18,19], TK domains [18,22]), low resolution
electron microscopy of the near full length/ full-length EGFR protein [25,26] together with
computational analyses [16]. For detailed discussions of EGFR biochemical mechanisms and
structures that have been elucidated, we direct the reader to other extensive reviews on the
subject [4–6,27].
Complicating the analysis of information transfer by EGFR is the fact that the receptor ECD
binds seven different growth factors that activate EGFR in mammalian systems [7,8] – these are
namely, epidermal growth factor (EGF), transforming growth factor-alpha (TGF-ɑ), epigen (EPI),
epiregulin (ER), betacellulin (BC), heparin-binding EGF (HB-EGF), and amphiregulin (AR) (Figure
1.1.C). It is well known that the different EGFR specific growth factors upon binding EGFR
initiate diverse growth factor-dependent signals in the cell interior [14,28–30]. Lesser is known
about how the chemical information encoded by the diverse growth factors is decoded by
EGFR into distinct outcomes of signaling and cell state. Preliminary clues can be gleaned from
high resolution structures of the EGFR ECD bound to a subset of these growth factors (EGF
[13,26], TGF-ɑ [12,26], EPI [14] and ER [14]), that reveal that these diverse EGFR specific
growth factors induce distinct structures locally within the ECD. Understanding how growth
factor dependent differences in ECD structure are then (1) allosterically propagated through the
intervening segments of the EGFR protein and (2) decoded into distinct intracellular signals has
been a focus of research in the Schepartz lab [17,20,31,21].
At the centre of this focus is the juxtamembrane region of EGFR [18,19]– this intervening
segment (spanning ~ 37 amino acid residues) is right in the middle of the allosteric network that
3

extends from the ECD to the tyrosine kinase domain and plays critical roles in multiple aspects
of EGFR signaling. In this section of my thesis, I will discuss the existing body of literature on
the EGFR JM, focusing on (i) the mechanistic roles of the JM in signal transduction, (ii) the
allosteric coupling of JM structure to the different EGFR domains and finally (iii) the interactions
of the JM with various intracellular components. Through this discussion, I hope to highlight the
fact that the JM region, through its various structures and interactions, acts as an essential
signal modulatory unit in the EGFR protein.
1.2. The juxtamembrane segment of the is necessary for EGFR kinase assembly and
activation. Several pieces of biochemical [18,19,32–35] and biophysical [18,19] evidence have
illustrated the indispensable role of the EGFR JM in receptor activation. Initial biochemical
analyses of EGFR kinase constructs with varying JM segment deletions revealed a clear
activatory role of the JM – As compared to EGFR kinase constructs where the complete JM
was present, constructs lacking the JM segment either in part or in entirety displayed (i)
reduced dimerization in vitro [18], (ii) reduced tyrosine kinase activity (~65-95% in vitro; 95% in
cellula) [33] and reduced catalytic efficiency (~10-70 fold reduction in kcat/ KM in vitro) [18].
Likewise, C-tail autophosphorylation activity was reduced in cellula for constructs lacking part
of/ the entire JM or where the entire JM is replaced by an unstructured (GGS)10 sequence, as
compared to the analogous intact full length/ intact intracellular domain constructs [32–34].
Biophysical analysis of the JM region either in conjunction with the kinase domain (using
crystallography) [18,19,22] or in isolation (using NMR) [18,36] have revealed finer structural
details of the individual elements of the JM that contribute to kinase assembly and activation.
The analysis of crystal structures of EGFR [19] and HER4 [18,37] kinase domains constructs
with their respective juxtamembrane segments revealed a conserved C-terminal portion of the
4

JM (EGFR residues 664-682; dubbed JM-B) (Figure 1.2.A) that stabilizes the EGFR kinases in
the catalytically competent asymmetric dimer conformation [22]. In this conformation, the JM-B
of the ‘receiver’/ ‘acceptor’ kinase wraps tightly around/ cradles the C-lobe of the ‘activator’/
‘donor’ kinase to provide additional stabilizing interactions between the two kinase domains
thereby enhancing their dimerization in solution (Figure 1.2.B) [18,19]. This was further
corroborated by mutagenesis of either all of the JM-B residues (except T669) individually to
alanine [19] or the interacting kinase domain C-lobe residues to either alanine or to reverse
charge [18] in the full length receptor – both of which had the effect of drastically reducing
growth factor dependent auto-phosphorylation activity in cellula [19]. Interestingly, the surface
of the kinase domain bound by the JM-B (residues 664-668) in the active state [18,19] is
roughly equivalent to the surface used by a portion of the C-tail (residues 986-990) to bind the
kinase domain in its inactive state (as seen in the crystal structure of an inactive kinase dimer
[18]). The authors in the study [18] suggested that the binding of the C-tail to the kinase in the
inactive state sterically occludes JM-B binding to facilitate kinase autoinhibition when the
catalytically competent asymmetric dimer is not formed.
Notably however, the JM-B portion of the JM segment by itself is insufficient for complete
activation of the EGF receptor kinases – As compared to kinase constructs where the complete
JM was present, the constructs lacking most of/ the complete N-terminal portion of the JM
(residues 645-664; dubbed JM-A) (Figure 1.2.A) had (i) reduced kinase dimerization (~40 fold
increase in KD) [18] (ii) reduced tyrosine kinase activity (~65% in vitro; 95% in cellula) [33] and
reduced catalytic efficiency (observed as ~10 fold decrease in kcat/ KM in vitro) [18]. The isolated
JM-A forms an amphipathic helix as detected by NMR [18,36] and also observed in a crystal
structure of an EGFR kinase construct containing the complete JM [19]. Furthermore,

5

mutagenesis of arginine residues in the JM-A

LRRLL659 helix motif (R656, R657) to glycine,

655

that weakens ɑ-helicity [38] was found to abrogate phospho-EGFR activity in cellula [18]. NMR
experiments using a peptide containing two copies of the JM-A attached by a short flexible
linker [18] revealed that the JM-A helices in this polypeptide assemble into a stable antiparallel
coiled coil dimer in solution which the authors proposed was necessary for driving proper
kinase assembly and activity in vitro (Figure 1.2.B). The assembly of the JM-A helices into an
antiparallel coiled coil was also documented in subsequent NMR and molecular modeling
studies of a polypeptide consisting of the JM and the directly preceding Transmembrane
domain (TM) segment (residues 618-673) [15,16]. It was observed that the coiled coil assembly
of the JM-A helices is directly coupled to dimerization of TM helices at an N-terminal G-x-x-x-G
motif that occurs in response to growth factor induced rearrangements in the ECD [15,16]
providing a clear picture of the allosteric network extending from the ECD to the JM.
Taken together the biochemical and biophysical data discussed so far implicate both the JM-A
and JM-B as essential for driving proper kinase assembly and activation – The JM-A forms an
antiparallel coiled coil dimer (which is coupled to structural rearrangements in the ECD and TM
induced by EGF binding) to enhance kinase proximity and dimerization [15,16,18] while the
JM-B provides additional stabilizing interactions to support formation of the catalytically
competent asymmetric kinase dimer [18,19] (Figure 1.2.B). While it is clear that the JM is
essential for kinase activation, it is challenging to study the structure and dynamics of the JM
at a high resolution in the context of the full length receptor in the dynamic environment of a
mammalian cell prompting two important questions. First, is the assembly of the JM-A helices
into an antiparallel coiled coil structure (as observed by NMR) [15,18] also observed in the full
length receptor in cells as a conduit for relaying growth factor binding by the ECD to support
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intracellular kinase activation? Secondly, how does a single structure [15,16,18,19] support the
subtle differences in growth factor induced ECD arrangements [12–14] to elicit diverse signaling
outcomes [14,29,30] by the receptor? To answer both questions, additional lines of evidence
need to be considered.
1.3. Using chemical biology tools to reveal the role of the JM-A coiled coil structure in
allosterically communicating growth factor identity. In order to interrogate the JM structure
and its role in communicating growth factor identity in full-length EGFR in cellula, Schepartz
and colleagues made use of a chemical biology tool called Bipartite Tetracysteine Display
[39,40]. This tool reports on protein conformation and association by exploiting the
bis-arsenical dye ReAsH [41,42] as a fluorogenic sensor. ReAsH bound through arsenic to two
ethanedithiol ligands is non fluorescent [41,43] and lights up only when coordinated to four
cysteine (Cys) side chains in an encoded tetracysteine motif that is reconstituted when the
protein is predictably folded and assembled [39,40] (Figure 1.2.C). The strict spatial
requirement of the assembly of a proper tetracysteine ReAsH binding site in order to observe
ReAsH fluorescence [39,40] makes the assay uniquely suited to visualise predicted interactions
within the protein containing the encoded tetracysteine motif in the complex environment of a
mammalian cell [39,40].
In an initial study, starting from the NMR structure of the JM-A based peptide [18], Scheck and
colleagues designed a series of full length EGFR variants with rationally placed Cys-Cys pairs
in the JM region to test the hypothesis that the intracellular JM-A segment assembles into an
antiparallel coiled coil upon EGF binding in cellula [20]. Using this approach, the authors
observed that upon binding EGF, the JM-A of EGFR adopts an antiparallel coiled coil
conformation [20], analogous to the structure observed previously by NMR [18] (Figure 1.2.D).
7

In this ‘EGF-type’ conformation the JM-A coiled coil dimer is characterized by a hydrophobic
mini-leucine zipper interface (formed by L655, L658 and L659) and decorated on the outside by
charged residues (K652, R656, R657, E661 and E663) [18,20]. Notably this particular assembly
of the JM-A was detected only when EGFR was bound to EGF (and HB-EGF) and not (i) when
EGFR was bound to TGF-ɑ or NRG, (ii) when JM-A helicity was interrupted by R656G/R657G
mutations and (iii) when assembly of the asymmetric kinase dimer was abrogated by a V924R
mutation [20]. Taken together the authors demonstrated the formation of an antiparallel coiled
coil structure in the JM-A of EGFR in cellula that uniquely encodes EGF (and HB-EGF) binding
by the ECD and supports the catalytically competent assembly of the kinase domain [20].
In a more comprehensive subsequent study, using a combination of molecular modeling of the
JM helices in silico and bipartite tetracysteine display in cellula, Doerner and colleagues
revealed the conformation of the JM-A when EGFR is bound to its seven different growth
factors [21]. Using RosettaDock [44] followed by iterative Monte Carlo randomization, the
authors observed in silico that the JM-A helices are able to stably assemble into several
classes of anti-parallel assemblies [21] (Figure 1.2.E). Some of these assemblies were found to
be consistent with the EGF-type structure predicted by NMR in vitro [18] and observed by
Bipartite Tetracysteine Display in cellula [20]. However, the in silico modeling also predicted a
completely separate class of antiparallel coiled coil assemblies that resembles an
‘‘inside-out’’version of the ‘EGF-type’ structure related by a 150 disrotatory rotation about each
helix axis [20]. Using Bipartite Tetracysteine Display, the authors observed that this JM-A coiled
coil conformation is adopted only when EGFR is bound to TGF-ɑ, EPI, ER and AR and not with
EGF or HB-EGF [20]. In this alternate ‘TGF-ɑ-type’ conformation the JM-A interface is
dominated by polar interactions at the antiparallel interface with the hydrophobic leucine
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residues pointing outwards [20]. The authors also found that when bound to BC, both the
EGF-type and TGF-ɑ-type were detected in the JM-A, which is supported by the assembly of
the JM-A into a third intermediate coiled coil interface predicted in silico [20]. Notably the type
of coiled coil structure adopted by the JM-A in response to growth factor binding by the ECD,
namely EGF-type (with EGF, HB-EGF) or TGF-ɑ-type (with TGF-ɑ, EPI, ER and AR) correlates
directly with cell state and downstream signaling outcomes elicited by these growth factors
[14,29,30]. Taken together, the assembly of discrete antiparallel coiled coil structures within the
JM-A not only links ligand-induced reorganization of the ECD to support kinase domain
activation but also uniquely specifies growth factor identity in context of the full length EGF
receptor in cells [20,21] (Figure 1.2.F). How do the alternate JM-A coiled coil structures tie into
the larger allosteric network of EGFR? For this additional lines of evidence need to be
considered.
1.4. Allosteric coupling of the JM-A coiled coil structures to the extracellular and TM
domains of EGFR. As discussed previously EGF binding by the ECD induces well documented
conformational rearrangements in the TM that are directly coupled to the formation of the
‘EGF-type’ coiled coil structure in the JM-A [15,16,18]. Much lesser is known in vitro about
what happens to the TM when the other growth factors (such as TGF-ɑ) are bound by the ECD.
Overlaying crystal structures of the EGFR ECD bound to EGF [13] and TGF-ɑ [12] reveal clear
differences in the arrangement of domain IV of the ECD [20] (that immediately precedes the
TM). How are these differences in ECD arrangement then transmitted through the TM to induce
the formation of the alternate JM-A coiled coil structures?
In order to test the hypothesis that differences in TM conformation propagate growth factor
induced rearrangements from the ECD to the JM-A, Sinclair and colleagues used a diverse set
9

of chemical biology and computational tools to probe the TM structure [17]. First, the authors
used a series of EGFR variants harboring single Cys substitutions within the TM, to evaluate
growth factor dependent changes in the extent of inter-chain Cys-Cys crosslinking (Figure
1.3.A) [17] similar to an approach used previously by Springer and colleagues [45]. The authors
observed that the extent of inter-chain Cys-Cys crosslinking in the N-terminal segment of the
TM (particularly at residues 624-629) differed significantly depending on the growth factor
bound to the ECD (high with EGF, HB-EGF, BC; low with TGF-ɑ, AR) [17] suggesting growth
factor dependent differences in TM helix association. Next, starting from an NMR structure of
the TM-JM fragment [15] the authors used a combination of in silico molecular modeling
(RosettaMPDock) [44,46,47] and Monte Carlo simulations (MPRelax) [46–48] to identify helical
conformations in the TM that are consistent with the assembly of the JM-A into the two distinct
‘EGF-type’ and ‘TGF-ɑ-type’ coiled coil structures detected in cellula (Figure 1.3.A) [20,21].
The authors observed that in silico the TM helices assemble into discrete dimer populations
that differ in both cross-location and cross-angle to support assembly of the alternate JM-A
structures – TM helix dimers with smaller cross-angles at multiple cross locations support
assembly of the EGF-type coiled coil structure in the adjacent JM, whereas helix dimers with
larger cross-angles at fewer cross locations induce the TGF-ɑ-type coiled coil (Figure 1.3.A)
[17]. Finally using bipartite tetracysteine display the authors demonstrated that by rationally
altering the cross-angle in the TM via mutation, the assembly of the JM-A could be biased into
either the EGF-type or TGF-ɑ-type or coiled coil structure independent of growth factor identity
[17]. Overall the alternate coiled coil structures formed within the JM-A are directly coupled to
the assembly of the TM helices into distinct conformations specified by cross location and
cross angle (Figure 1.3.A) [17].
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1.5. Allosteric coupling of the JM-A coiled coil structures to the mutational/
pharmacological status of the EGFR kinase domains. It is well known that mutations in the
EGFR kinase domain are most frequently implicated in patients with non-small-cell lung cancer
(NSCLC) [49]. One common mutation (L834R) induces ligand-independent activation and
oncogenic signaling [50,51] that accounts for nearly 7−8% of all EGFR mutations found in
patient populations [52–54]. Patients whose tumors harbor L858R EGFR often respond to
first-generation tyrosine kinase inhibitors (TKIs) such as erlotinib (OSI-774) [55,56] and gefitinib
(ZD1839/Iressa) [57,58] that act by competing reversibly with ATP [59,60]. However these
patients frequently regress due to a second kinase domain mutation (T766M) that lowers
inhibitor potency [61,62]. This double mutant (L834R/ T766M EGFR) can be targeted by
second- and third-generation TKIs such as afatinib (BIBW-2992) [63,64], rociletinib (CO-1686)
[65,66] , WZ4002 [67] and osimertinib (AZD-9291) [68–70] that bind to the kinase of the mutant
EGFR by irreversibly alkylating a conserved active site cysteine side chain (C797).
Using bipartite tetracysteine display, Lowder and colleagues found that perturbations within the
intracellular kinase domain either due to oncogenic mutation or specific TKI binding are
propagated over long distances to allosterically modulate the coiled coil assembly of the JM-A
helices [31] – The authors found that the JM-A helices of EGFR bearing the oncogenic mutation
L834R constitutively assemble into the EGF type structure in cellula (Figure 1.3.B) [31]. In
contrast the JM-A helices in EGFR variants bearing the L834R/T766M double mutations
constitutively assemble into a TGF-ɑ-type coiled coil structure as detected in cellula (Figure
1.3.B) [31]. Furthermore when cells expressing the double mutant L834R/T766M EGFR are
treated with 2nd gen TKIs such as afatinib (BIBW-2992), the coiled coil structure remains
unaffected [31]. In contrast treatment with double mutant selective 3rd gen TKIs such as
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WZ-4002, CO-1686 (rociletinib) and AZD9291 (Tagrisso/ osimertinib) have the effect of entirely
flipping the coiled coil structure into the alternate ‘EGF-type’ structure [31] (Figure 1.3.B). While
the exact structural mechanism by which the transition of the JM-A from one coiled coil state to
another is mediated by oncogenic mutations/ 3rd gen TKI binding, remains a subject of
ongoing investigation, overall it is evident that the JM-A structure is allosterically linked to the
pharmacological status of the kinase domain (Figure 1.3.B) [31].
1.6. The juxtamembrane region is a hotspot for interactions with diverse intracellular
components that regulate EGFR biology. The JM region of EGFR is a hotspot of interactions
with diverse intracellular cellular components (membrane lipids and intracellular proteins), many
of which modulate EGFR signaling and downstream biology. One of these is the interaction of
the JM-A with the inner leaflet of the lipid bilayer of the cell membrane as revealed by detailed
biochemical [15,18] and computational analyses [16]. This interaction is twofold – Firstly, the
three leucine side chains within the

LRRLL659 helical motif of the JM-A [18] are found to be

655

buried in the hydrophobic part of the lipid membrane [15,16]. Second, positively charged
residues within the juxtamembrane segmentv(in addition to those in the kinase domain) interact
electrostatically with negatively charged anionic phospholipids present in the inner leaflet of the
cell membrane [15,16,71]. This interaction provides an additional layer of receptor
auto-inhibition in the absence of growth factor activation, by reducing the proximity of JM-A
helices from adjacent monomers thereby preventing their dimerization and [15,16,18,72]. The
JM region has also been shown to interact with many intracellular proteins, such as Calmodulin
[32,72–76], Nck adaptor protein [77], GɑS [78], PKC [79–84], p38MAPK [85,86], PI4K [87], AP2
[88,89], TRAF4 [90], ARNO [91] and PKD[92]. Table 1.1 lists the details of the experiments
evaluating these interactions, the binding sites of these protein interactors and their observed/
proposed biological effects. Notably the JM sequence also contains multiple sites and cryptic
motifs that are recognized by intracellular machineries to elicit receptor upregulation (T669;
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phosphorylation by p38MAPK reduces the downregulation of EGFR [85,86]), receptor
downregulation (T654; phosphorylation by protein kinase C attenuates EGFR activity
[79,80,82,84]), a dileucine motif (L679, L680; recognized by AP-2 for clathrin mediated
endocytosis [88,89]), motifs for basolateral sorting [93,94] and nuclear translocation [95,96].
(Figure 1.4.)
1.7. Conclusion. In this chapter we have discussed the evidence in the literature that points to
the importance of the juxtamembrane region of EGFR in multiple aspects of growth factor
induced receptor activation. Within the juxtamembrane, both the JM-A and JM-B are essential
for driving proper kinase assembly and activation – During the course of growth factor activation
of EGFR, the JM-A forms an antiparallel coiled coil dimer to enhance kinase proximity and
dimerization [15,16,18] while the JM-B provides additional stabilizing interactions to support
formation of the catalytically competent asymmetric kinase dimer [18,19]. The JM-A is also
critical for communicating growth factor identity – the JM-A can assemble into discrete
antiparallel coiled coil structures to uniquely specify the identity of the ECD bound growth
factor in context of the full length EGF receptor in cells [20,21]. Furthermore, the JM-A structure
is allosterically controlled by the confirmation within the TM segment helices specified by cross
location and cross angle [17]. The JM-A structure is also allosterically coupled to the
mutational/ pharmacological status of the kinase domain [31]. Lastly, the JM is a hotspot for
interactions with diverse intracellular cellular lipid and protein components with potential roles in
modulating EGFR signaling and downstream biology. Overall, in this chapter, we discuss how
the JM segment of EGFR through its various structures and interactions, acts as an essential
signal modulatory unit in the EGFR protein and is not simply a passive connector of the
extracellular sensory (ECD) and intracellular effector (kinase) domains.
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Figure 1.1. The Epidermal growth factor receptor – structure, mechanism of activation
and intracellular signaling. (A) Schematics illustrating the distinct regions and domains of
EGFR. (B) Schematic illustrating the mechanism of EGF induced activation of EGFR. (C)
Schematic illustrating the diverse growth factor induced intracellular signaling of EGFR. EGFR
binds to seven different kinds of extracellular growth factor to initiate multiple intracellular
signaling cascades that are critical for diverse cellular functions.
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Figure 1.2. The juxtamembrane segment of EGFR is essential for kinase activation and
for allosterically encoding growth factor identity in cells. (A) Schematics illustrating the
domain location and sequence of the JM-A and JM-B portions of the juxtamembrane domain
of EGFR. (B) The JM-A and JM-B portions of the juxtamembrane segment are both essential
for catalytically competent assembly and activation of the EGFR kinase in vitro– the JM-A
assembles into an antiparallel coiled coil structure in vitro to increase proximity and
dimerization of kinase domains; the JM-B provides stabilizing interactions to the asymmetric
kinase dimer interface. (C) The fluorogenic dye ReAsH is quenched when bound to two
ethanedithiol ligands because of free rotation about the carbon-sulfur bond. When bound to
proteins containing four proximal Cys thiols in bipartite tetracysteine motif, rotation is inhibited
and the ReAsH fluoresces providing a readout on conformation. (D) Schematic summary of the
methodology used to apply bipartite tetracysteine display to probe the assembly of the JM-A
coiled coil structure of EGF activated EGFR in cells. (E) Schematic summary of the
computational methodology used to identify other stable antiparallel coiled coil structures that
can be adopted by the JM-A. (F) Alternate coiled coil structures formed within the JM-A of
EGFR are sufficient for allosterically encoding the identity of the growth factor bound to the
extracellular domain – schematic summary of the results of the bipartite tetracysteine display
experiments. Helical wheel diagrams showing axial views of inter-helix JM-A segment packing
in EGF- and TGF-α-type coiled coils.
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Figure 1.3. The JM-A coiled coil structure is allosterically connected to the structure of
the TM domain and pharmacological status of the kinase domain. (A) Schematic summary
of disulphide cross-linking experiments and in silico modeling of the TM-JM segment to
evaluate the allosteric coupling of the TM and JM segments. The JM-A coiled coil structure is
controlled by the cross angle and cross-location of the TM helices. (B) Oncogenic mutations
L834R and L834R/ T766M lock the JM-A into the EGF-type or TGF-ɑ-type coiled coil
structures respectively. Treatment with third generation tyrosine kinase inhibitors (TKIs) specific
for L834R/ T766M EGFR flip the coiled coil structure of L834R/ T766M EGFR from the
TGF-ɑ-type structure into the EGF-type structure.
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Figure 1.4. Sequence motifs and protein binding sites in the juxtamembrane region.
Schematic illustrating the location and sequence of known cryptic motifs and protein binding
sites in the juxtamembrane segment of EGFR. See also Table 1.1.
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Table 1.1. Protein interactions with the juxtamembrane domain of EGFR

Protein
interactor

Interaction
site in JM

Experimental Method and
Constructs used

Biological effect/ Experimental
summary

Ref.

Calmodulin
(CaM)

R645–Q660

Cross-linking/ CaM and
GST-JM peptide (645–660)

CaM binding to JM is dependent
on intracellular Ca2+

[73]

R647, T654

SPR/CaM and immobilized
GST-JM peptide (644–688)

pT654 inhibit CaM binding (with
T654D, and PKC treatment)

[32]

R645-Q660

Radioactive probe
conjugated to a JM peptide
(645–660)

Intracellular Ca2+/CaM induces
dissociation of JM from a PC/PS
membrane

[72]

R645-Q660

Fluorescence probe
conjugated JM (645–660)

R645-Q660

FRET/ EGFR TM-JM
peptide (R622–Q660)

Intracellular Ca2+/CaM induces
dissociation of JM from a POPC
membrane containing PIP2

[76]

R645-Q660

EGFR activation in cellula
and western blotting/
(CaM antagonist treatment/
CaM-KO cells/ chelation of
Ca2+/ mutagenesis of
CaM-binding domain)

Abrogating CaM binding/
depleting intracellular Ca2+
inhibits EGFR activation

[75]

Nck adaptor
protein

H648, I649,
R647-T654
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C-1H HSQC/ JM peptide
(645-672) or (644-674)
titrated with unlabeled
GB1-Nck1-2

The JM segment of EGFR
interacts with Nck.

[77]

GɑS

R645-R657

IP and western blotting of
GɑS with JM peptides
(645-657) or (679-692)

Treatment with JM peptides
induces phosphorylation of GɑS

[78]

PI4K

R645-E663

IP and western blotting of
of PI4K with EGFR JM
peptide (645-663)

Treatment with JM peptide
increases PI4P activity

[87]

A431 cells/ P-32 labeling
phosphorylation assay

PKC is related to phosphorylation
of the EGFR

[80,81]

T654

A431 cells/ P-32 labeling
phosphorylation assay

PKC phosphorylates the JM of
EGFR at T654

[79,82]

T654

A432/ B82 cells transfected
with WT or T654A-EGFR/
I-125 EGF binding assay

EGF binding by WT EGFR is lost
for upon PKC activation (by
phorbol esters)

[83]

T654

CHO cells transfected with
WT or T654E-EGFR/
I-125 EGF binding assay

EGF binding by WT EGFR is lost
upon PKC activation; T654EEGFR has lower C-tail pY activity
compared to WT-EGFR upon
PKC activation.

[84]

Protein
kinase C
(PKC)
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[74]

T669

A431 cells/ P-32 labeling
phosphorylation assay

p38MAPK phosphorylates the
EGFR JM at T669 and changes
its binding and kinase state.

[85]

T669

MDA-MB-468 or CHO-K1
cells transfected with WT
or T669A-EGFR/ Western
blotting & P-32 labeling
phosphorylation assay

p38MAPK phosphorylates the
EGFR JM at T669; T669
phosphorylation by p38MAPK
induces EGFR internalization.

[86]

AP-2

L679, L680

NR6 cells transfected with
WT or L679A,L680A-EGFR
Internalization/ recycling
assay with I-125 EGF;
radioactivity measurement,
Lamp-1 immunostaining
and confocal microscopy.

The dileucine motif in the EGFR
juxtamembrane formed by L679,
Leu680 is critical for the
post-endocytic endosomal
sorting of EGFR to lysosomes/
degradation pathway

[88,89]

TRAF4

G672-I682

HeLa cells with WT EGFR
or Δ672-682 EGFR; EGFR
phosphorylation assay by
immunoblotting; HSQC of
15
N TRAF4 with EGFR
peptide (672-682)

TRAF4 binds to the EGFR JM-B
(672-682) and is essential for
EGF-induced activity of EGFR

[90]

ARNO

R645-I682

Microscale thermophoresis
(MST) between EGFR-JM
and Sec7 domain of ARNO
1
H, 15N-HSQC of EGFR-JM
titrated with ARNO-Sec7

ARNO binds to the JM region of
EGFR and competes with the
binding interaction of the JM with
CaM and anionic phospholipids

[91]

Protein

T654, T669

CHO-K1 cells with eGFPEGFR for Raster image
correlation spectroscopy
(RICS) or T654/T669
phospho-mimetics or PKD1
mutant with kinase activity
abrogated (K612W)

PKD1 phosphorylates the EGFR
JM at T654/T669; T654/T669
phosphorylation by PKD shifts
the monomer-dimer equilibrium
of EGF-bound EGFR towards the
monomeric state.

[92]

p38MAPK

kinase D
(PKD)
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Chapter 2. Discrete coiled coil rotamers form within the EGFRvIII juxtamembrane domain
2.1. ABSTRACT
Mutations in the ECD of EGFR are implicated in the development of glioblastoma multiforme
(GBM), a highly aggressive form of brain cancer [97–100]. Most notable in GBM pathology is
the variant of EGFR known as EGFRvIII, that results from an in-frame deletion of exons 2-7,
which encode EGFR ECD residues 6-273 [101–103]. This deleted region includes an
auto-inhibitory tether [23], whose absence, alongside unique disulfide interactions [104] within
the truncated ECD, supports constitutive assembly of an active asymmetric kinase dimer
[22,97,100]. Previous studies have shown that growth factors binding to the ECD of wild type
(WT) EGFR leads to the formation of two distinct coiled coil dimers in the JM-A segment whose
identities correlate with downstream phenotype [17,20,21]. One coiled coil contains leucine
residues at the interhelix interface (EGF-type), whereas the other contains charged and polar
side chains (TGF-α-type) [17,20,21]. It has been proposed that growth factor-dependent
changes in the ECD structure and adjacent TM helix are transduced into distinct coiled coil
structures in the JM-A region [17,20,21]. Herein we demonstrate that in the absence of this
growth factor-induced signal, the JM-A of EGFRvIII is able to adopt both EGF-type and
TGF-α-type structures, providing direct evidence for this hypothesis [105]. These studies
confirm that the signals that define the identity of the JM-A coiled coil begin within the ECD,
and support a model in which growth factor-induced conformational changes are transmitted
from the ECD through the TM helices to favor different coiled coil isomers within the JM.
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2.2. Introduction – EGFRvIII a prominent mutation in GBM is constitutively activated.
EGFRvIII is the most common EGFR mutation associated with glioblastoma multiforme (GBM)
[99,106–109], a high-grade brain tumor associated with exceptionally high fatality [110].
Multiple studies have correlated the EGFRvIII expression with poor survival [111,112]. Unlike
EGFR variants in NSCLC that bear mutations within the kinase domain [50,51,113–115] that
can be targeted selectively with TKIs [63,65,67,68,116,117], EGFRvIII contains a wild type (WT)
kinase domain, hindering the development of selective inhibitors [100,118–121].
EGFRvIII is generated by an in-frame deletion of 801 base pairs from exons 2-7 of the ECD
[100–103] (Figure 2.1.A). As a result, the receptor lacks residues 6-273, which include most of
ECD domains I and II. Included in this region is one of three residues (Y246) that interacts with
D563 and K585 on domain IV to hold the WT receptor in an autoinhibited conformation
[12,13,23,122] (Figure 2.1.B,D). The absence of the Y246 autoinhibitory latch causes EGFRvIII
to be constitutively activated [12,13,108,123] (Figure 2.1.B). EGFRvIII also lacks the domain II
dimerization arm that in WT EGFR is necessary for growth factor-induced ECD dimerization
[12,13] (Figure 2.1.C,D). Despite this absence EGFRvIII is able to dimerize via formation of
disulphide bonds between cysteine residues exposed as a result of ECD truncation [104]. This
disulfide-induced extracellular dimerization event, like growth factor-induced dimerization,
supports intracellular formation of an asymmetric kinase dimer that signals constitutively
through the MAPK and AKT pathways (among others) to initiate oncogenic activity in the cell
[98,106–108,124].
The EGFR ECD does more than simply bind growth factors and promote dimerization - it is an
essential component of an allosteric pathway linking growth factor binding to kinase activation
[6,27]. Previous studies have shown that growth factors binding by WT EGFR leads to the
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assembly of two distinct coiled coil structures in the EGFR JM-A [17,20,21]. One of these
structures dubbed the ‘EGF-type coiled coil’ is favored when WT EGFR is activated by
epidermal growth factor (EGF) and heparin-binding EGF-like growth factor (HB-EGF), and is
distinguished by a hydrophobic, leucine-rich coiled coil interface observed by NMR [15,18].
The other coiled coil structure dubbed the ‘TGF-α-type coiled coil’ is favored when WT EGFR is
activated by transforming growth factor-α (TGF-α), epigen, epiregulin, and amphiregulin, and is
distinguished by electrostatic interactions at the helical interface with leucines decorating the
outside surface [21] (Figure 2.1.E). Formation of EGF- and TGF-α-type coiled coils within the
EGFR JM-A correlate with distinct intracellular phenotypes, including the direction of endocytic
trafficking, receptor lifetime, and the relative flux through alternative downstream signaling
pathways [21,29]. Given that EGFRvIII is activated constitutively (even in the absence of growth
factor induced ECD rearrangements), it provides a unique opportunity to interrogate the relative
stabilities of the EGFR JM-A segment in the absence of signals emanating from a WT ECD.
Here we utilize bipartite tetracysteine display [39,40] to demonstrate that in the absence of
growth factor-induced signals, the JM of EGFRvIII is able to constitutively adopt both EGF-type
and TGF-α-type structures [105]. Our studies provide further evidence for an allosteric pathway
that links growth factor-induced binding to the extracellular domain to JM coiled coil structure
and kinase activation.
2.3. Using bipartite tetracysteine display to probe the structure of the EGFRvIII JM-A.
Our initial experiments sought to probe the existence and structure of the coiled coil formed in
the JM-A region of intact EGFRvIII dimers in cellula. To do so, we made use of the chemical
biology tool bipartite tetracysteine display (Figure 2.1.F) [39,40]. This tool exploits the
bis-arsenical dye ReAsH [41] as a fluorogenic sensor that lights up only when bound to four
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cysteine (Cys) side chains in a discrete molecular array [43]. Our previous work identified a set
of CysCys-containing WT EGFR variants whose dimers bind ReAsH and fluoresce only when
the JM is assembled into either an EGF-type coiled coil (CCH-1) or the isomeric TGF-α-type
coiled coil (CCH-10) [17,20,21] (Figure 2.2.A). The resulting ReAsH fluorescence, detected
using TIRF microscopy (TIRF-M), provides an in-cell readout of JM structure within intact EGF
receptors [17,20,21]. Visualizing ReAsH fluorescence using TIRF-M restricts fluorophore
excitation and emission to a small (100−200 nm) cell surface plane and diminishes the signal
from non-specific cytosolic ReAsH staining [20].
To probe for formation of the EGF-type or the TGF-α-type coiled-coil within the JM of intact
EGFRvIII receptors, the CCH-1 or CCH-10 CysCys mutations were integrated into the EGFRvIII
sequence to generate vIII-CCH-1 and vIII-CCH-10, respectively (Figure 2.2.B). In control
experiments, we confirmed that vIII-CCH-1 and vIII-CCH-10 (each carrying an N-terminal
FLAG-tag) were expressed in CHO-K1 cells, localized to the cell surface, and underwent the
expected phosphorylation at C-tail residues Y1068 and Y1086 in the absence and presence of
saturating (16.7 nM) EGF or TGF-α (Figure 2.5.).
In the bipartite tetracysteine display experiments, CHO-K1 cells expressing vIII-CCH-1 or
vIII-CCH-10 were stimulated with growth factor (or not), incubated with ReAsH, washed, and
immuno-stained. Receptor expression was monitored using a fluorescently labeled antibody to
an N-terminal FLAG epitope. Using TIRF-M, the level of both cell surface ReAsH fluorescence
(red) and EGFR expression (green) was quantified across multiple cells (67 - 161) expressing
either EGFR or EGFRvIII variants. The cell-surface ReAsH fluorescence detected (over
background) was normalized to the surface EGFR-expression detected (over background) to
calculate the fold-increase in ReAsH fluorescence (Figure 2.3.A,B). Cells expressing WT-CCH-1
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or WT-CCH-10 displayed levels of normalized ReAsH fluorescence relative to background that
mirrored previous reports [17,20,21] (Figure 2.3.A,B). By contrast, cells expressing vIII-CCH-1 or
vIII-CCH-10 showed an almost 2-fold increase in normalized ReAsH fluorescence relative to
background both in the absence of any growth factor (1.86 ± 0.09 and 1.79 ± 0.09,
respectively) as well as when treated with EGF (1.81 ± 0.10 and 1.70 ± 0.08) or TGF-α (1.80 ±
0.08 and 1.84 ± 0.10) (Figure 2.3.A,B). The fold-increase in ReAsH fluorescence observed for
cells expressing vIII-CCH-1 or vIII-CCH-10 was comparable to that observed when WT-CCH-1 or
WT-CCH-10 are activated with EGF and TGF-α, respectively [17,20,21]. Previous work
examining the JM-A coiled coil status of WT EGFR activated with different growth factors
[17,20,21], or of constitutively active EGFR kinase domain mutants [31], has always revealed a
preference formation of a single JM-A coiled coil structure over the other. The absence of this
preference in the case of EGFRvIII is consistent with two fundamentally different scenarios:
The first possible explanation is that the structure of the constitutively active EGFRvIII is a
mixture of dimers containing the EGF-type and TGF-α-type JM coiled coils (if not others). The
second possibility is that the JM of constitutively active EGFRvIII can easily assume multiple
different conformations including but not limited to the EGF-type and TGF-α-type JM coiled
coils; the associated increased flexibility could also support ReAsH binding and induced
fluorescence (Figure 2.2.C).
To differentiate between these two possibilities, we designed a third set of CysCys containing
EGFRvIII variant, namely vIII-CCH-4 (Figure 2.2.A,B). In vIII-CCH-4 the four Cys residues within
the JM are located too far apart to bind ReAsH in either the EGF-type or TGF-α-type
conformation [20]. In the EGF-type structure, the Cys residues are located at positions g and e
(as well as g’ and e’); in the TGF-α-type structure the Cys residues are located at positions g
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and b (as well as g’ and b’). If the JM-A of EGFRvIII adopts either the EGF-type or the
TGF-α-type antiparallel coiled coil, then cells expressing vIII-CCH-4 should show little or no
ReAsH fluorescence. Conversely, if the JM-A of EGFRvIII flexibly adopts multiple different
conformations, then cells expressing vIII-CCH-4 should show high ReAsH fluorescence. In
control experiments, we verified that vIII-CCH-4 was expressed in CHO-K1 cells and
constitutively phosphorylated at C-tail positions Y1068 and Y1086 (Figure 2.5.).
Using bipartite tetracysteine display, the fold increase of ReAsH fluorescence of CHO-K1 cells
expressing variants WT-CCH-4 and vIII-CCH-4 was evaluated in the absence and presence of
EGF and TGF-α. As expected, with cells expressing WT-CCH-4, no significant fold increase in
ReAsH fluorescence is observed when the cells are activated with either EGF (1.09 ± 0.05) or
TGF-α (1.06 ± 0.06) or not stimulated with any growth factor (1.01 ± 0.04) [20] (Figure 2.3.A,B).
Interestingly, cells expressing vIII-CCH-4 also showed little or no ReAsH labeling and
fluorescence both without growth factor activation (1.19 ± 0.06) and when the cells were
stimulated with either EGF (1.17 ± 0.06) or TGF-α (1.19 ± 0.09). These results favor a model in
which the EGFRvIII JM assembles constitutively into a mixture of two different antiparallel
coiled coils of roughly equal stability. The data are less consistent with a model in which the JM
segment of EGFRvIII can easily assume multiple different conformations.
2.4. Conclusion.
WT EGFR interacts through its ECD with seven different growth factors [7,8]. These factors
induce different structures within the cytoplasmic juxtamembrane segment (JM) of the dimeric
receptor and propagate different growth factor-dependent signals to the cell interior [17,20,21].
Previous work has defined a model to explain how EGFR supports growth factor-dependent
differences in intracellular signaling. This model begins with small but significant growth
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factor-dependent differences in the structure of the bound ECD, especially in domain IV as it
tracks into the TM helix [12,13,17,20]. These differences lead to TM helix dimers that differ in
both cross location and cross angle [17]. TM helix dimers characterized by smaller cross angles
at multiple cross locations induce the EGF-type coiled coil in the adjacent JM-A, whereas helix
dimers with larger cross angles at fewer cross locations induce the TGF-α -type coiled coil
(Figure 2.4.A) [17].

EGFRvIII provides a unique opportunity to test this model, as kinase

activation occurs constitutively in the absence of either growth factor binding or activating
kinase domain mutations. Here we make use of bipartite tetracysteine display to demonstrate
that in the absence of this growth factor-induced signal, the JM-A of EGFRvIII adopts both
EGF-type and TGF-α-type structures within the juxtamembrane segment [105]. We show that
in the absence of growth factor-induced ECD rearrangements, the JM-A adopts a well-ordered
configuration that appears to be a mixture of EGF-type and TGF-α-type structures [105]
(Figure 2.4.A). These results suggest that the EGF-type and TGF-α-type JM-A coiled coils
possess roughly equal stability in the context of the intact full-length receptor (Figure 2.4.B).
Overall, our work provides further evidence for an allosteric pathway linking structural changes
induced by growth factor-induced binding by the ECD to coiled coil assembly in the JM-A and
consequent kinase activation.
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2.5. Methods and Materials
Materials. Unlabeled recombinant human epidermal growth factor (EGF) (#CB40052) was
purchased from Corning. Unlabeled recombinant human transforming growth factor-α (TGF-α)
(#T7924) and mouse monoclonal (M2) anti-FLAG primary antibody (#F1804) were purchased
from Sigma. 2,3-dimercapto-1-propanol (BAL) (#AC115300250) was purchased from Acros
Organics. Rabbit monoclonal anti-phospho-EGF receptor Tyr1173 (53A5) (#4407), rabbit
polyclonal anti-phospho- EGF receptor Tyr1086 (#2220), rabbit polyclonal anti-phospho-EGF
receptor Tyr1068 (#2234), rabbit anti-α-tubulin (#2155) primary antibodies as well as goat
polyclonal

anti-Rabbit,

HRP-conjugated

(#7076)

HRP-conjugated

(#7074)

and

goat

polyclonal

anti-mouse,

secondary antibodies were purchased from Cell Signaling

Technology. CHO-K1 cells were purchased from the American type Culture Collection (ATCC).
Dulbecco’s phosphate buffered saline (DPBS) (#14190), fetal bovine serum (FBS) (#26140079),
penicillin-streptomycin (10,000 U/mL) (#15140122), ReAsH-EDT2 (#T34562) and goat polyclonal
anti-mouse, AlexaFluor488-conjugated secondary antibodies (#A10667) were purchased from
ThermoFisher Scientific. EGFR UniProtKB accession ID: P00533.
Plasmids and Cloning. All plasmids used in bipartite tetracysteine display and related assays
are derived from a parent plasmid (pcDNA3.1), generously donated by the Kuriyan Group
(University of California, Berkeley), which contains the sequence of full-length WT EGFR with
an N-terminal FLAG tag [18,22]. Mutations and deletions were introduced into pcDNA3.1 using
Quikchange Lightning site-directed mutagenesis (Agilent) and primers (Integrated DNA
Technologies) listed in Table 2.1.
Cell Culture. CHO-K1 cells were purchased from ATCC and maintained at 37°C, 5% CO2, in
F12K Medium (Corning) supplemented with 10% fetal bovine serum and pen-strep (100
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I.U./mL penicillin and 100mg/mL streptomycin). Cell densities were determined with a
Cellometer Auto T4 automated counter. Transient transfection of CHO-K1 cells was performed
via use of the Transit-CHO Transfection Kit, according to the manufacturer’s instructions (Mirus
Bio LLC).
Bipartite Tetracysteine Display. ReAsH labeling was performed as described previously
[17,20,21], by treating CHO-K1 cells that were transiently transfected with plasmids containing
the appropriate EGFR variants in the presence of an endocytosis/ATP synthesis inhibition
cocktail in F12-K media (10 mM NaN3, 2 mM NaF, 5mM 2-deoxy-D-glucose), for 1hr at 37°C.
Cells were then stimulated without/with 100ng/mL of EGF (16.7nM) or TGF-α (16.7nM) for 30
min at 4°C prior to labeling. Cells were then washed once with endocytosis/ATP synthesis
inhibition cocktail in F12K media before incubation with ReAsH labeling solution (2mM ReAsH,
20mM BAL in F12K media) for 60 min at 37°C. Cells were then washed and incubated with
endocytosis inhibitor-containing F12K media supplemented with 100 mM BAL for 10 min at
37°C. The media was removed, and the cells were fixed using 4% paraformaldehyde for 25 min
at room temperature. Cells were then washed with DPBS and blocked with 10% BSA in DPBS
for 30 min at 37°C. Cells were then labeled with primary antibody (mouse anti-Flag, 1:1000
dilution in 10% BSA in DPBS) for 1hr at 37°C, washed three times with 10% BSA in DPBS,
then incubated with secondary antibody (AlexaFluor488-conjugated goat anti-mouse, 1:2000
dilution in 10% BSA in DPBS) for 1hr at 37°C. Cells were then washed two times with 10%
BSA in DPBS, washed once with DPBS, then nuclear stained with Hoechst-33342 (1.62mM in
DPBS) for 5 min at 37°C. Cells were then washed once with DPBS and stored in DPBS at 4°C
prior to imaging. Labeled cells were then analyzed via TIRF microscopy, conducted on a Leica
Microsystems AM TIRF MC DMI6000B fitted with an EM-CCD camera (Hamamatsu) with HCX
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PL APO 63x/1.47 oil corrective objectives, as described previously [17,20,21]. Images were
analyzed as described previously [17,20,21]. Briefly, raw data from TIRF microscopy were
analyzed using ImageJ 643. Fluorescence intensities of ReAsH and AlexaFluor 488 (EGFR
levels) were quantified, and the fold increase of ReAsH fluorescence relative to background
was normalized for EGFR expression levels. Normalized values of ReAsH fold-increases were
plotted

using

Prismv7.0

(for

Mac,

GraphPad

Software,

La

Jolla

California

USA,

www.graphpad.com), where n represents number of cells quantified, and error bars represent
the standard error of the mean. One-way ANOVA followed by a Dunnett multiple comparisons
test was performed.
Autophosphorylation analysis. Western blot analysis of EGFR autophosphorylation in
transiently transfected CHO-K1 cells was performed as described previously [17,20,21].
CHO-K1 cells, transiently transfected with a plasmid encoding the appropriate EGFR variant,
were collected (5x105 cells), resuspended in 200 mL of serum free F12K media, stimulated with
100ng/mL of EGF (16.7nM) or TGF-α (16.7nM) for 5 min at 37°C (or not), pelleted, washed with
serum-free F12K media, pelleted again, then lysed in 100 mL of lysis buffer (50mM Tris, 150mM
NaCl, 1mM EDTA, 1mM NaF, 1% Triton X-100, pH 7.5, 1x complete protease inhibitor cocktail
(Roche), 1x PhosStop), on ice for 1hr. Clarified cell lysates were then subjected to reducing
10% polyacrylamide SDS-PAGE electrophoresis and transferred to immuno-blot PVDF
membranes. Membranes were blocked with 5% milk in TBS-T Buffer (50mM Tris, 150mM NaCl,
0.1% Tween, pH 7.4) for 1hr followed by an overnight incubation at 4°C with the indicated
primary (rabbit or mouse) antibodies. Blots were then washed with TBS-T and incubated with
either anti-rabbit or anti-mouse goat HRP-conjugate secondary antibodies (Cell Signaling
Technology) for 1hr at room temperature, then washed with TBS-T. Blots were then visualized
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using Clarity Western ECL reagents (BioRad). Displayed blot images have been adjusted for
brightness/contrast using ImageJ/ FIJI [125] and have been cropped to highlight band signals
for full-length EGFR (~170 kDa) or EGFRvIII (~145 kDa).
Table 2.1: Mutagenesis Primers*
S.No.

Primer Name

Sequence (5’-3’)

1.

EGFRvIII, forward

5’-cgagccgtgatctgtcaccacataattTTTCTTTTCCTCCAGTCCGGA
GC-3’

2

EGFRvIII, reverse

5’-gacaagggctccggactggaggaaaagaaaAATTATGTGGTGACAG
ATCACGGCTC-3’

Mutagenesis primers for the insertion of cysteines to generate the CCH-1, CCH-4, and CCH-10
variants of EGFRvIII have been previously described [20,21].
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Figure 2.1. Comparison between wild type (WT) epidermal growth factor receptor (EGFR)
and EGFRvIII. (A) Schematics illustrating the distinct regions and domains of WT EGFR and
EGFRvIII. EGFRvIII lacks amino acid residues 6-273 of the extracellular domain (ECD) (dashed
line). (B) Surface model of the auto-inhibited conformation of the WT EGFR ECD (PDB ID:
1NQL). Subdomains are color-shaded for visualization (I, III: deep teal; II, IV: pale cyan). The
ECD is held in an auto-inhibited conformation by intramolecular interactions between residues
in domains II and IV. (C) Surface model of the WT EGFR ECD dimer bound to EGF (PDB ID:
3NJP). Domains are color-shaded as previously indicated to visualize subdomain movement
upon EGF binding. One of the dimeric partners is shaded light for clearer visualization. (D)
Surface model of the auto-inhibited EGFR ECD with the portions missing in EGFRvIII shaded
light. The ECD deletion prevents formation of auto-inhibitory intramolecular interaction between
domain II and IV. (E) Helical wheel diagrams showing axial views of inter-helix juxtamembrane
segment packing in EGF- and TGF-α-type coiled coils. (F) The fluorogenic dye ReAsH is
quenched when bound to two ethanedithiol ligands because of free rotation about the
carbon-sulfur bond. When bound to proteins containing four proximal Cys thiols, rotation is
inhibited and the fluorescence is de-quenched.
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Figure 2.2. Probing EGFRvIII JM structure using bipartite tetracysteine display. (A)
Sequence of the juxtamembrane (JM) regions of vIII (WT EGFR numbering) alongside those of
vIII CCH-1, CCH-10 and CCH-4. JM residues in the vIII sequence that are mutated to Cys in
vIII-CCH-1, vIII-CCH-10 and vIII-CCH-4 are colored red. (B) Helical wheel diagrams illustrating
axial views of idealized inter-helix packing in EGF- and TGF-α-type coiled coils. The helical
diagrams shaded with red background indicate a conformation that is suitable for ReAsH
binding with the individual vIII variants. (C) Two models to account for ReAsH binding by both
vIII-CCH-1 and vIII-CCH-10.
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Figure 2.3. The juxtamembrane segment of EGFRvIII exists as a mixture of EGF- and
TGF-α-type coiled coils. (A) Representative TIRF-M images of CHO-K1 cells illustrating
ReAsH labeling (red fluorescence) and expression (green fluorescence) of FLAG-tagged CCH-1,
CCH-10 and CCH-4 variants of WT EGFR and EGFRvIII in the absence and presence of EGF or
TGF-α stimulation (16.7 nM). Scale bars represent 10 µm. (B) Bar Plots illustrating the
quantification of TIRF-M results from ‘n’ cells as a fold-increase in expression-corrected ReAsH
fluorescence over background. Error bars represent s.e.m., ****p<0.0001, ***p<0.001, **p<0.01,
*p<0.05 from one-way ANOVA with Dunnett’s post-analysis accounting comparison to the WT
control for each case without growth factor treatment. n.s., not significant. See also Figure 2.5.
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Figure 2.4. (A) Cartoon illustrating the preferred conformation of the JM coiled-coil in WT
EGFR and EGFRvIII. In WT EGFR, the JM conformation is influenced by the identity of the
growth factor bound to the ECD. When bound to EGF, the JM adopts an antiparallel coiled coil
characterized by a leucine-rich, hydrophobic interface, when bound to TGF-α, the antiparallel
coiled coil is characterized by a polar interface. In the constitutively active EGFRvIII, in the
absence of growth factor-induced ECD rearrangements, both EGF-type and TGF-α coiled coil
conformations are adopted. (B) Hypothetical energy well diagrams illustrating the different
energy landscapes of the JM region in WT EGFR and EGFRvIII.
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Figure 2.5. CCH-1, CCH-10 and CCH-4 variants of WT EGFR and EGFRvIII are expressed
and phosphorylated as expected. Immunoblots comparing the relative expression and
activity (as judged by the level of receptor autophosphorylation at Y1068, Y1086) of CCH-1,
CCH-10 and CCH-4 variants of WT EGFR and EGFRvIII with the corresponding EGFR variant
lacking CysCys substitutions within the JM. In each case, transiently transfected CHO-K1 cells
were stimulated with 100ng/mL (16.7nM) EGF or TGF-α (or serum free media) for 5min at 37℃.
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Chapter 3. Investigating the role of the JM-A coiled coil structure on EGFR trafficking and
degradation.
Disclosure and authorship
This text of this chapter contains material adapted from a manuscript submitted to the
peer-reviewed journal eLife for review:
“Coiled coil control of growth factor and inhibitor-dependent EGFR trafficking and
degradation”, Mozumdar, D., Chang, S. H.-H., Quach, K., Doerner, A., Schepartz, A.
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Chapter 3. Investigating the role of the JM-A coiled coil structure on EGFR trafficking and
degradation.
3.1. ABSTRACT.
EGFR exhibits biased intracellular signaling – growth factor or mutation-dependent changes in
the conformation and/or dynamics of the receptor elicit distinct intracellular outcomes of EGFR
signaling, biology and cell fate. We report that a two-state coiled coil switch located within the
juxtamembrane segment (an essential component of the cytosolic dimer interface) controls
many outcomes associated with activated EGFR. The position of this allosteric switch (defined
by the identity of the JM-A coiled coil structure) controls the path of EGFR endocytic trafficking
and whether or not the receptor is degraded in lysosomes. The identity of the JM-A coiled coil
structure also predicts kinase-independent effects of oncogenic EGFR mutations (L834R/
T766M) and the ability of clinically relevant tyrosine kinase inhibitors (TKIs) to promote efficient,
lysosomal degradation of oncogenic EGFR. These findings provide a model for biased
intracellular signaling by EGFR, insights into kinase-independent activities of the receptor and
clinically relevant TKIs, and identify new strategies for modulating EGFR lifetime.
3.2. Introduction.
Receptor tyrosine kinases in the EGFR family play diverse and critical roles in cell proliferation,
differentiation, and migration [3,4,6]. Aberrant activation of EGFR family members, via
overexpression or mutation, is associated with many human cancers [10,11,126]. Although
much work on EGFR has focused on its activation by EGF [1], EGFR is activated by at least
seven different growth factors including TGF-α, EPI, ER, BC, HB-EGF, and AR [7,8], and
transmits these activation events into distinct intracellular phenotypes [28,29,127–129]. Growth
factor-dependent biased signaling through EGFR has been previously attributed to differences
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in the physical properties of the growth factors [28,127,129] or their receptor complexes
[128–130]. EGFR is also activated constitutively by mutations in the kinase domain, the
extracellular domain, or elsewhere [6,10,11,126]; these mutations are causally linked to many
human cancers [126].
Previous work has shown that the binding of most growth factors to the ECD of EGFR induces
the formation of one of two rotationally isomeric coiled coils within the juxtamembrane
segment (JM) [21], an essential element of the cytoplasmic dimer interface [18,19]. Binding of
EGF or HB-EGF induce a coiled coil in the JM-A defined by a leucine-rich inter-helix interface
(EGF-type) [20], whereas AR, EPI, ER, or TGF-α induce an isomeric structure whose interface is
charged and polar (TGF-α-type) [21]. JM coiled coil preference is also influenced allosterically,
by point mutations within one of the G-x-x-x-G motifs of the TM helix [17], oncogenic ECD
[105] and kinase domain mutations [31], and, in the case of drug-resistant L834R/T766M
EGFR, the pharmacologic status of its kinase domain [31].
While it is clear that the structure of the JM-A segment is coupled allosterically to the different
EGFR domains, this very coupling complicates strategies to investigate how and whether
distinct coiled coil structures in the JM-A influence outcomes associated with biased signaling.
To better understand the relationship between JM-A coiled coil structure and EGFR biology, we
designed a set of kinase-active EGFR mutants that effectively shift the equilibrium between JM
coiled coil isomers. These EGFR mutants assemble into dimers that favor one coiled coil or the
other in a manner that is independent of the activating growth factor. Using these and other
“decoupling” mutants, we demonstrate that coiled coil identity alone is necessary and sufficient
for defining the pathway of EGFR trafficking into degradative (Rab7+) or recycling (Rab11+)
endosomes and ultimately whether EGFR is degraded within lysosomes. The identity of the
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coiled coil in the JM-A also predicts the trafficking and lifetime of oncogenic EGFR mutants
and reveals kinase-independent effects of FDA-approved small molecule TKIs. These
discoveries increase our understanding of the molecular mechanism used for biased signaling
in ErbB-family receptors and suggest new strategies for purposefully controlling protein traffic
and lifetime along the endocytic pathway.
3.3. Results
3.3.1. Design of EGFR decoupling mutants via mutations in the JM structure. We initially
sought to identify and design a set of functional, full-length EGFR variants that could be used
to isolate the cellular role of the JM-A by decoupling the coiled coil structure of the JM-A from
growth factor identity [21,17,20]. It is well known that salt bridges at the e and g positions of
model coiled coils influence stability and orientation [131], while changes at the a and d
positions influence oligomeric state [132]. These studies suggested that the relative stability of
the EGF- and TGF-α-type coiled coils formed within an intact EGFR dimer could be controlled
by the presence/ absence of salt-bridging residues for a specific coiled coil structure at
positions e and g (Figure. 3.1.A). We hypothesized that by rationally removing interactions that
stabilized a given JM-A coiled coil structure would raise its free energy relative to the other and
shift the equilibrium between the two structures (Figure 3.2.A). The result would be a set of
EGFR variants that favored only a single JM-A coiled coil structure, regardless of the identity of
the growth factor bound to the ECD. Such a design strategy would necessitate that two
interconverting coiled coil structures are equally favorable – indeed our previous work with
EGFRvIII revealed that the EGF- and TGF-α-type coiled coil structures are equally favorable
when no growth factor-dependent signal emerges from the extracellular domain [105].
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To test this hypothesis, a pair of EGFR variants (E661R and KRAA) were generated that
contained one or two amino acid substitutions to selectively disrupt salt bridges unique to
either the TGF-α- or EGF-type JM coiled coils (Figure. 3.1.A and Figure. 3.2.B). In E661R
EGFR, a single charge-reversing mutation is located at distal c and c’ positions of the heptad
repeat when the JM folds into an EGF-type coiled coil, but at proximal e and e’ positions when
it folds into a TGF-α-type structure. Thus the JM-A in E661R EGFR should favor the EGF-type
structure because it lacks a TGF-α-type-specific salt-bridge. By contrast, in KRAA EGFR, the
two charge-eliminating substitutions K652A/ R656A are located at distal c,g and c’,g’ positions
of the coiled coil repeat when the JM is assembled into the TGF-α-type structure, but at
proximal e, a positions when assembled into the EGF-type structure. Thus the JM-A in KRAA
EGFR should favor the TGF-α-type structure because it lacks two EGF-type-specific salt
bridges (Figure. 3.1.A). As a control for our experiments, we designed a T654D EGFR variant –
this mutation occupies the c or e position of a coiled coil repeat when the JM assembles into
the EGF- and TGF-α-type structures, respectively (Figure. 3.1.A) and should not affect coiled
coil stability. In control experiments, we verified that EGFR variants (containing mutations in the
JM) could be expressed in CHO-K1 cells (which express little or no endogenous EGFR [133]),
trafficked to the cell surface, and were phosphorylated at multiple tyrosine residues within the
C-tail when treated with saturating (16.7 nM) EGF or TGF-α (Figure. 3.2.C).
3.3.2. Validating EGFR decoupling mutants. With functional EGFR mutants in hand, we made
use of the bipartite tetracysteine display [20], to test the hypothesis that activated E661R and
KRAA EGFR dimers would favor an EGF-type or TGF-α-type coiled coil, respectively,
regardless of the identity of the activating growth factor. Bipartite tetracysteine display exploits
the pro-fluorescent bis-arsenical dye ReAsH [41], which lights up only when bound to four Cys
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side chains (two from each EGFR monomer) in a defined array [43]. Previous work identified a
CysCys-containing EGFR variant whose dimer binds ReAsH only when its JM-A is assembled
into an EGF-type type structure (CCH-1 EGFR); another CysCys-containing EGFR variant
(CCH-10 EGFR) forms dimers that induce binds ReAsH only when the TGF-α-type coiled coil is
formed [21]. For the bipartite tetracysteine display experiments, variants of CCH-1 and CCH-10
EGFR containing E661R or KRAA mutations were generated. In control experiments, we
verified that all CysCys containing JM mutants were phosphorylated at multiple tyrosine
residues within the C-terminal tail when treated with EGF or TGF-α; EGFR T654D was
somewhat less active (Figure. 3.2.D).
The three sets of EGFR CCH-1 and CCH-10 variants were expressed in CHO-K1 cells,
stimulated with EGF or TGF-α, incubated with ReAsH, and the level of ReAsH fluorescence
relative to EGFR-expression determined using TIRF microscopy (TIRF-M) (Figure 3.1.B,C).
TIRF-M excites fluorophores in an extremely thin axial region, typically within ~100 nm of the
cell surface, thus the measured fold-increases in ReAsH fluorescence provide a read-out of JM
coiled coil conformation within EGFR molecules at or near the plasma membrane. As expected
[21], a significant fold-increase in ReAsH fluorescence was observed when cells expressing WT
EGFR CCH-1 EGFR are treated with EGF (2.00 ± 0.06) but not TGF-α (1.26 ± 0.03), or when
cells expressing WT CCH-10 EGFR were treated with TGF-α (1.52 ± 0.05) and not EGF (0.97 ±
0.04). By contrast, cells expressing E661R CCH-1 EGFR showed a significant fold-increase in
ReAsH fluorescence regardless of whether the cells were treated with EGF (2.66 ± 0.14) or
TGF-α (2.60 ± 0.12), suggesting that the EGF-type structure formed in both cases. Little or no
fold-increase in ReAsH fluorescence was observed when cells expressing E661R CCH-10
EGFR were treated with EGF (1.14 ± 0.08) or TGF-α (1.10 ± 0.07) (Figure 3.1.B,C).
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In a similar way, cells expressing KRAA CCH-10 EGFR displayed a significant fold-increase in
ReAsH fluorescence regardless of whether the cells were treated with EGF (1.40 ± 0.05) or
TGF-α (1.32 ± 0.05), and little increase was observed in cells expressing KRAA CCH-1 EGFR
(1.59 ± 0.19-fold (EGF); 1.21 ± 0.14-fold (TGF-α)) (Figure 3.1.B,C). Analogous variants
containing T654D mutations behaved like WT EGFR, as expected (Figure 3.2.E,F)) and no
fold-increase in ReAsH fluorescence was observed in the absence of added growth factor.
These data indicate that no matter which growth factor is bound to the EGFR ECD, E661R
EGFR assembles into an active dimer containing an EGF-type coiled coil, whereas KRAA EGFR
assembles into an active dimer containing a TGF-α-type coiled coil. These results confirm that
the mutations embodied by E661R and KRAA EGFR can effectively decouple growth factor
identity from coiled coil status.
3.3.3. Trafficking of E661R and KRAA EGFR. A quintessential growth factor-dependent
characteristic of EGFR is its path of receptor trafficking following endocytosis [134].
Unactivated EGF receptors at the cell surface are internalized into Rab4-associated early
endosomes and recycled back to the cell surface where they accumulate. Activated receptors
are trafficked first to EEA1-positive (EEA1+) early endosomes [135]. The pathway then splits,
and receptors are sorted into vesicles defined by the presence of either Rab11 (Rab11+) or
Rab7 (Rab7+). Rab11+ vesicles deliver EGFR back to the cell surface (recycling pathway) [136]
whereas the Rab7+ vesicles deliver EGFR to late endosomes and lysosomes where the
receptors are ultimately degraded (degradative pathway) [137]. Trafficking from EEA1+ early
endosomes into recycling or degradative endosomes is known to be growth factor-dependent:
when stimulated with EGF, EGFR preferentially traffics into Rab7+ endosomes and is ultimately
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degraded [137]; when stimulated with TGF-α, EGFR preferentially traffics into Rab11+
endosomes and returns to the cell surface [30].
The dependence of the path of EGFR trafficking on growth factor identity post-endocytosis has
been previously attributed to differences in the pH-dependent ligand occupancy of receptors
following [28,127]. In particular, TGF-α dissociates from EGFR at higher pH than does EGF;
ligand dissociation at earlier points along the endocytic pathway is believed to lead ultimately
to receptor sorting. Although the pH-dependent model is simple, it is inconsistent with reports
that TGF-α-bound EGFR continues to signal within endosomes [30,138]. We thus asked
whether the coiled coil status of the JM-A could also control the pathway of EGFR trafficking. If
so, then EGFR mutations that favor the EGF-type (E661R) coiled coil in activated dimers would
bias trafficking into Rab7+ endosomes (degradative pathway), whereas those that favor the
TGF-α-type structure would bias trafficking into Rab11+ endosomes (recycling pathway).
We used confocal microscopy to trace the time-, mutation, and growth factor-dependent
pattern of EGFR trafficking and organelle co-localization following growth factor stimulation.
CHO-K1 cells expressing FLAG-tagged WT, E661R, KRAA or T654D EGFR were incubated first
on ice with EGF or TGF-α to allow growth factor binding and then at 37 oC in growth factor-free
media to initiate endocytosis and receptor trafficking. After 8 or 40 min, the cells were
immuno-stained to visualize EGFR and assess the extent of colocalization with EEA1, Rab7, or
Rab11. After 8 min, WT EGFR, E661R, KRAA, and T654D EGFR all co-localize with the early
endosome marker EEA1 (Figure 3.3.A,B) and not with Rab7 (Figure 3.3.C,D) or Rab11 (Figure
3.3.E,F), regardless of whether the cells were stimulated with EGF or TGF-α. After 40 min, the
colocalization of all activated receptors with EEA1 decreases to non-significant levels [29]
(Figure 3.5.A,B). These results confirm that the growth factor-dependent trafficking of all EGFR
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variants studied here proceeds initially through EEA1+ early endosomes regardless of JM
coiled coil status or growth factor identity.
We used the same workflow to evaluate the trafficking pattern of FLAG-tagged WT, E661R,
KRAA and T654D EGFR at 40 min post growth factor incubation. WT EGFR and T654D EGFR
both colocalized preferentially with Rab7 when activated with EGF (MCC = 0.78 ± 0.05 (WT)
and 0.71 ± 0.05 (T654D)) (Figure 3.4.A,C and Figure 3.5.C,D) and with Rab11 when activated
with TGF-α (MCC = 0.62 ± 0.06 (WT) and 0.60 ± 0.06 (T654D)) (Figure 3.4.B,C and Figure
3.5.C,D). In contrast, while E661R still colocalized significantly with Rab7 when activated with
EGF, it also colocalized significantly with Rab7 when activated with TGF-α (Figure 3.4.A-C).
The extent of EGFR colocalization with Rab7 upon TGF-α activation was low (MCC = 0.09 ±
0.02) for WT EGFR but moderate (MCC = 0.44 ± 0.07) for the E661R variant (Figure 3.4.A-C).
Similarly, the extent of colocalization with Rab11 upon TGF-α activation was high (MCC = 0.62
± 0.06) for WT EGFR but only moderate (MCC = 0.34 ± 0.10) for the E661R variant (Figure
3.4.A-C). Overall, these results indicate that the E661R mutation biases EGFR trafficking into
Rab7+ endosomes independent of whether EGF or TGF-α is used to activate the receptor.
The inverse set of results were obtained when the pathway of KRAA EGFR trafficking was
examined: KRAA EGFR colocalized significantly with Rab11 (and not Rab7) whether activated
with EGF or TGF-α (Figure 3.4.A-C). The extent of EGFR colocalization with Rab11 upon EGF
activation was low (MCC = 0.18 ± 0.03) for WT EGFR but moderate (MCC = 0.41 ± 0.08) for the
KRAA variant (Figure 3.4.A-C). Similarly, the extent of colocalization with Rab7 upon EGF
activation was high (MCC = 0.78 ± 0.05) for WT EGFR but only moderate (MCC = 0.29 ± 0.06)
for the KRAA variant (Figure 3.4.A-C). These results indicate that the KRAA mutation biases
EGFR trafficking into Rab11+ endosomes regardless of whether EGF or TGF-α is used to
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activate the receptor. Taken together, these results indicate that the pathway of EGFR
trafficking is influenced by the structure formed within the JM region that links the TM region to
the kinase domain. We note, however, that the biasing of EGFR trafficking is not a perfect
“on/off” switch: while the E661R substitution increases the fraction of EGFR that traffics into
Rab7+ endosomes in the presence of TGF-α, a small fraction of TGF-α-activated E661R EGFR
traffics into Rab11+ endosomes (Figure 3.4.A-C). Indeed, the extent of phosphorylation at
C-tail residues Y1045, Y1068, and Y1173 did not obviously correlate with JM mutational state
(Figure 3.6.A-C).
3.3.4. Mutations within the EGFR transmembrane helix that allosterically influence JM
coiled coil status control the pathway of receptor trafficking. Mindful of the fact that E661R
and KRAA EGFR contain mutations within the JM coiled coil itself which could influence
functional intra- or intermolecular protein interactions, we turned to a new set of EGFR
decoupling variants in which JM coiled coil identity is controlled allosterically by point
mutations in the adjacent transmembrane segment (TM) [17]. Substitution of phenylalanine for
a single glycine (G628) at the final position of the N-terminal G-x-x-x-G motif of the EGFR TM
(G628F EGFR) generates a receptor dimer with an EGF-type JM coiled coil, regardless of
whether the receptor is activated by EGF or TGF-α–just like E661R EGFR [17]. Likewise,
substitution of the beta-branched valine residue at position 628 (G628V EGFR) generates a
receptor dimer with a TGF-α-type coiled coil, regardless of whether the receptor is activated by
EGF or TGF-α–just like KRAA EGFR [17]. Substitution of G628 with alanine (G628A EGFR)
generates a receptor that behaves like WT EGFR. Since these TM variants contain an unaltered
JM, their functional intra- or intermolecular protein interactions should be preserved. As a
result, the trafficking patterns they follow should provide an unadulterated view of the
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relationship between JM conformational status and EGFR trafficking. If JM coiled coil structure
is both necessary and sufficient to direct the pathway of EGFR trafficking, then G628F and
G628V EGFR should traffic into only Rab7+ or Rab11+ endosomes, respectively, regardless of
how they are activated, whereas G628A EGFR should behave like WT EGFR and traffic in a
growth factor-dependent manner. In control experiments we verified that G628F, G628V, and
G628A EGFR colocalize after 8 min with EEA1 (Figure 3.7.A,B) and not with Rab7 (Figure
3.7.C,D) or Rab11 (Figure 3.7.E,F); colocalization with EEA1 falls to expected levels after 40
min (Figure 3.7.G,H).
Indeed, after 40 minutes, although the extent of G628A EGFR co-localization with Rab7 and
Rab11 was growth factor-dependent, the localization of G628F and G628V EGFR were not
(Figure 3.8.). When stimulated with EGF, G628A EGFR co-localized preferentially with Rab7
(MCC = 0.38 ± 0.06) (Figure 3.8.A,C) and not Rab11 (MCC = 0.13 ± 0.03) (Figure 3.8.B,C);
when stimulated with TGF-α, G628A EGFR co-localized preferentially with Rab11 (MCC = 0.33
± 0.03) (Figure 3.8.B,C) and not Rab7 (MCC = 0.13 ± 0.03) (Figure 3.8.A,C). By contrast,
G628F EGFR colocalizes exclusively with Rab7 whether stimulated with EGF (MCC = 0.48 ±
0.05) or TGF-α (MCC = 0.37 ± 0.03) (Figure 3.8.A,C) and not with Rab11 (MCC = 0.11 ± 0.05
and 0.14 ± 0.04 for cells stimulated with EGF and TGF-α-, respectively) (Figure 3.8.B,C).
Conversely, G628V EGFR colocalizes exclusively with Rab11 whether stimulated with EGF
(MCC = 0.65 ± 0.03) or TGF-α (MCC = 0.65 ± 0.07) (Figure 3.8.B,C) and not with Rab7 (MCC
= 0.12 ± 0.02 and 0.16 ± 0.03 for cells stimulated with EGF and TGF-α-, respectively) (Figure
3.8.A,C). Here, when the coiled coil status of the JM-A is fixed by distal mutations, the switch
in trafficking pattern was observed to be complete: G628F EGFR, whose JM contains an
EGF-type coiled coil, trafficks along the degradative pathway whereas G628V EGFR, whose JM
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contains a TGF-type coiled coil, trafficks along the recycling pathway. Furthermore, in this case
the extent of phosphorylation at C-terminal tail residues Y1045,Y1068, and Y1173 correlates
with JM mutational state (Figure 3.9.A-C).
3.3.5. Coiled coil control of EGFR degradation. The differences in endocytic trafficking seen
with EGFR TM mutants that influence JM structure result in predictable changes in EGFR
lifetime (Figure 3.10.A,B). The lifetime of WT and G628A EGFR depends on growth factor
identity in the expected way [29,30]. Following EGF stimulation, WT and G628A EGFR levels
decrease rapidly and the fraction of intact receptor detected after 90 minutes is low (41-45%),
whereas the fraction of intact EGFR detected after 90 minutes is high when cells are stimulated
with TGF-α (94-92%)(Figure 3.10.A,B). By contrast, G628F EGFR is degraded rapidly
regardless of whether the receptor was activated with EGF or TGF-α, with 42% and 60% of the
intact receptor remaining after 90 min following EGF or TGF-α treatment, respectively (Figure
3.10.A,B). Conversely, G628V was degraded slowly following treatment with EGF or TGF-α,
with 92% and 95% of the intact receptor remaining after 90 min, respectively (Figure 3.10.A,B).
Control experiments using inhibitors of either lysosomal or proteasomal function confirmed that
EGFR degradation occurred within lysosomes (Figure 3.10.A,B). Thus, the presence of a single
point mutation in the TM segment and its long-range effect on JM conformation are necessary
and sufficient to dictate the pathway of intracellular trafficking (Figure 3.8) and the extent of
EGFR degradation in lysosomes (Figure 3.10.).
3.3.6. Tyrosine kinase inhibitors influence the trafficking path and lifetime of
L834R/T766M EGFR. The allosteric network coordinating information transfer between the
ECD, TM, and JM regions of EGFR also includes the cytoplasmic kinase domain and its
pharmacologic state [31,17,139]. Kinase domain mutations associated with drug-resistant
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non-small cell lung cancer (L834R/T766M) [50] generate constitutively active receptors whose
JM-A assemble preferentially into the TGF-α-type structure [31]. The structure of the JM coiled
coil shifts into the EGF-type structure when L834R/T766M EGFR is inhibited by selective
third-generation tyrosine kinase inhibitors (TKIs) such as WZ-4002 [67], CO-1686/ Rociletinib
[65], or the clinically approved AZD-9291/ Osimertinib/ Tagrisso [68]. Previous work has shown
that L834R/T766M EGFR is constitutively endocytosed and recycled in H1975 cells [140], as
predicted by the position of its JM coiled coil switch (preferential assembly into the TGF-α-type
JM-A structure). Here we asked whether this pattern of post-endocytic trafficking is also
observed in CHO-K1 cells expressing L834R/T766M EGFR, whether it is affected by
L834R/T766M EGFR-selective TKIs, and whether differences in trafficking lead to predictable
changes in L834R/T766M EGFR lifetime.
Using confocal microscopy, we evaluated the pattern of endocytic trafficking and sub-cellular
localization of L834R/T766M EGFR in CHO-K1 cells in the presence and absence of second(Afatinib), third- (AZD-9291, CO-1686, WZ-4002), and fourth-generation (EAI045) TKIs [117].
These small molecule EGFR inhibitors differ in mechanism of engagement (covalent vs.
non-covalent), EGFR specificity (WT vs. DM; monomer vs. dimer-specific), and binding site
(ATP vs. allosteric) (Figure 3.11.). All of these TKIs predictably decreased the levels of EGFR
auto-phosphorylation (Figure 3.12.A). As anticipated from data in H1975 cells [140], after 40
min uninhibited L834R/T766M EGFR colocalizes with Rab11 (MCC = 0.48 ± 0.03) (Figure
3.11.C,D) and not Rab7 (MCC = 0.17 ± 0.01) (Figure 3.11.A,B), favoring the recycling pathway
as expected for activated receptors that contain a TGF-α-type JM coiled coil [31].
Afatinib-inhibited L834R/T766M EGFR also colocalizes with Rab11 (MCC = 0.46 ± 0.04)
(Figure 3.11.C,D) and not Rab7 (MCC = 0.14 ± 0.02) (Figure 3.11.A,B) after 40 min, again
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favoring the recycling pathway expected for activated receptors that contain a TGF-α-type JM
coiled coil [31]. By contrast, when covalently inhibited by AZD-9291, CO-1686, or WZ-4002, all
third-generation TKIs that selectively and covalently inhibit L834R/T766M EGFR, the extent of
L834R/T766M EGFR colocalized with Rab7 increases and colocalization with Rab11 decreases
(Figure 3.11.B,D). Notably, these changes are not observed in cells expressing L834R/T766M
EGFR and treated with the fourth-generation inhibitor EAI045 (Figure 3.11.B,D), which binds
noncovalently in a pocket adjacent to that of AZD-9291 [117]. EAI045 differs from AZ-9291,
CO-1686, and WZ-4002 in both engagement mode and binding site within the EGFR kinase
domain, suggesting that the observed differences in receptor trafficking likely result from a
common allosteric change in EGFR structure induced by these three small molecules that
guides the receptor along the degradative arm of the endocytic pathway.
Finally we asked whether the change in endocytic trafficking induced by AZD-9291, CO-1686,
and WZ-4002 also resulted in L834R/T766M EGFR degradation. We observed that treatment of
L834R/T766M EGFR with AZD-9291, WZ-4002, and CO-1686 led to markedly (> 75%) reduced
receptor levels after 12 hours when compared to untreated samples (Figure 3.11.E and Figure
3.12.B). In contrast, uninhibited, Afatinib-treated, and EAI045-treated L834R/T766M EGFR
levels remained steady (Figure 3.11.E and Figure 3.12.B). The TKI-induced degradation of
L834R/T766M EGFR induced by AZD9291, CO-1686, and WZ-4002 was inhibited completely
by chloroquine, while lactacystin had no effect (Figure 3.11.E and Figure 3.12.B). Neither
chloroquine nor lactacystin affected the levels of L834R/T766M EGFR when mock-treated or in
the presence of TKIs that failed to induce L834R/T766M EGFR degradation (Figure 3.11.E and
Figure 3.12.B). For all cases inspected, predictable levels [141,65,68,117] of phosphorylated
L834R/T766M EGFR were detected at Y1045 (Figure 3.11.F and Figure 3.12.C) and Y1068
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(Figure 3.11.G and Figure 3.12.D). Thus, third-generation TKIs that engage the ATP-binding
pocket [141,65,68], allosterically induce an EGF-type structure within the JM segment [31], and
traffic the receptor into Rab7+ endolysosomes (Figure 3.11.A,B), also induce significant levels
of L834R/T766M EGFR degradation through a lysosomal, as opposed to proteasomal
mechanism (Figure 3.11.E and Figure 3.12.B).
3.3.7. Discussion. EGFR is an essential, membrane-embedded sensor that communicates and
integrates growth factor-dependent signals into diverse cellular phenotypes [6,142]. It is also
one of the most potent oncogenes in human cancers [11,126] and remains an insufficiently
addressed therapeutic target. EGFR is activated by growth factors that bind to the receptor
extracellular domain (ECD) and by diverse mutations [6]; in both cases the result is a dimeric
receptor with one of two coiled coils within the cytoplasmic juxtamembrane segment (JM)
[17,20,21,31] and a catalytically active asymmetric kinase dimer [22]. Despite its clear
therapeutic significance, the mechanism by which EGFR decodes growth factor identity and/or
mutational status into distinct and dynamic cellular signaling programs has remained elusive. In
part, this knowledge gap results from the absence of a high-resolution view of how the full
length EGFR acts as an allosteric unit to communicate information across multiple domains
and a complex lipid bilayer in cells. But a more complete understanding of EGFR function is
also precluded by allostery itself; how can one separate the activities of two or more protein
domains whose conformational landscapes are dynamic and themselves tightly coupled?
3.3.8. The JM coiled coil is a rotational toggle switch. In this work, we use structural,
biochemical, and chemical biology tools to decouple the conformational landscape of the JM
from both the extracellular domain and the kinase domain without loss of EGFR activity. Using
these mutants and tools, we identify the cytoplasmic juxtamembrane segment as an essential
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EGFR processing center. The JM-A receives inputs from both the TM helices and the kinase
domain and assembles into one of two rotationally isomeric coiled coils [17,20,21,31].
Together, these coiled coils contain all of the information necessary to specify both the
direction of trafficking along the endocytic pathway and EGFR lifetime. These results support a
model in which the pathway of endocytic trafficking following EGFR activation is determined by
JM coiled coil status and not by growth factor-dependent differences in the EGFR-ligand
complex stability as previously proposed [29,30,127]. The different effects of EGFR-selective
growth factors also do not correlate with receptor dimer strength [14], as EGF and TGF-α both
induce high affinity ECD dimers but traffic differently. Further corroborating these results are
recent findings [26] providing a high-resolution view of how the binding of EGF and TGF-α to
the extracellular domain alter the orientation of the dimeric receptor as it tracks into the
membrane-embedded transmembrane helix. As changes in transmembrane helix orientation
are known to bias JM conformation in cells [17], together these results provide a clear picture
of how conformation changes within the EGFR extracellular domain are transduced into
alternative JM conformations, and how alternative JM conformations are necessary and
sufficient to control fundamental EGFR biology.
The structures of the EGF- and TGF-α-type coiled coils differ not only in the residues that
mediate helix-helix interactions but also in the external surface available for intra- and
intermolecular interaction. In the EGF-type structure, the residues at the c, f, and b positions of
the coiled coil repeat are charged and polar [18], whereas these positions are hydrophobic (all
leucine) in the TGF-α-type structure (Figure 1a). A sophisticated molecular dynamics-derived
model of the active full-length receptor dimer [16] shows the receiver kinase JM in the
EGF-type structure with direct interactions between the receiver kinase JM latch (residues
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664-681) and the charged surface of the activator kinase C-lobe. The details of these
interactions and/or their dynamics would be different were the JM assembled into the
TGF-α-type structure, whose interaction surface is hydrophobic, not polar and charged. The
different interaction surfaces could interact differently with the kinase domain to alter the
position (and thus accessibility) of the C-terminal tail, which is believed to localize near the JM
[6,18,19] or alter the precise arrangement of acceptor and receiver kinase domains relative to
one another [16,22,143] and thereby influence their inherent substrate specificity. These
different interaction surfaces could also play a direct role by differentially recruiting known
JM-interacting factors such as, Nck adaptor protein [77], PKC [79], p38MAPK [86], AP2
[144,145] calmodulin [91] and ARNO [91], which in turn bias EGFR signaling and the
consequent trafficking route. The presence of a LeuLeu motif on the outside surface of the
TGF-α-type coiled coil is especially intriguing, as LeuLeu motifs elsewhere within EGFR
(notably the JM-B region and C-terminal tail) are docking sites for endosomal sorting factors
[144,145].
3.3.9. Altered trafficking and degradation as kinase-independent EGFR and TKI activities.
Small molecule EGFR inhibitors that bind near or within the ATP binding pocket and
monoclonal antibodies targeting the extracellular domain have produced impressive therapeutic
beneﬁts to responsive cancers [146]. However, neither therapeutic modality offers sustained
patient benefits, in large part because of acquired and innate resistance mechanisms [147,148].
There is a growing realization that EGFR possesses kinase-independent pro-survival functions
in cancer cells [149,150] that are insufficiently inhibited by either monoclonal antibodies or
small molecules that inhibit kinase activity alone. Our results support a model in which
pro-survival kinase-independent EGFR functions are related to JM-dependent differences in
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trafficking that avoid lysosomal degradation and receptor downregulation. Indeed, both
EGFRvIII (implicated in glioblastoma multiforme) and L834R/T766M EGFR (implicated in
NSCLC) avoid Cbl binding, ubiquitination, and degradation [151,152]. In the case of
L834R/T766M EGFR, this kinase-independent activity is reversed by TKIs that shift the JM
coiled coil equilibrium to promote lysosomal trafficking and degradation. Identification of the
as-yet-unknown factors that mediate this trafficking could serve as a new strategy for targeted
protein degradation that complements both traditional PROTAC-like strategies and lysosomal
targeting strategies based on cell surface receptor engagement [153–155].
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3.3.10. Materials and Methods
Materials. Antibodies. Goat polyclonal anti-Rabbit, Horseradish Peroxidase (HRP)-conjugated
(#7074),

Goat

polyclonal

anti-Mouse,

HRP-conjugated

(#7076),

Rabbit

monoclonal

anti-Phospho-EGF ReceptorTyr1173, (53A5) (#4407), Rabbit polyclonal anti-Phospho-EGF
Receptor Tyr1086 (#2220), Rabbit polyclonal anti-Phospho-EGF Receptor Tyr1068 (#2234),
Rabbit

polyclonal

anti-Phospho-EGF

Receptor

Tyr1045

(#2237),

Rabbit

monoclonal

anti-α-Tubulin (#2125), Rabbit monoclonal anti-vinculin (#13901), Rabbit monoclonal anti-EEA1
(C45B10) (#3288), Rabbit monoclonal anti-Rab7 (D95F2) XP (#9367), Rab11 (D4F5) XP Rabbit
mAb (#5589), Anti-mouse IgG (H+L) and F(ab')2 Fragment Alexa Fluor® 555-conjugate (#4409)
were purchased from Cell Signaling Technologies (CST). Mouse monoclonal (M2) anti-Flag
(#F1804), Anti-FLAG® M2 Affinity Gel (#A2220) were purchased from Millipore Sigma. Goat
anti-Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 488®-conjugate
(#A11001), IgG (H+L) Cross-Adsorbed Goat anti-Rabbit, Alexa Fluor™ 488 (#A11008), were
purchased from ThermoFisher Scientific.
Chemicals and Recombinant Proteins. F-12K Medium (#10-025-CV), Dulbecco’s Phosphate
Buffered Saline (DPBS) (#14190), Fetal Bovine Serum (FBS)–Heat Inactivated (#11082147),
Penicillin/Streptomycin (#1514012), Non-enzymatic Cell Dissociation Solution (#13151014),
RestoreTM Western Blot Stripping Buffer (#21059), Hoechst 33342, Trihydrochloride, Trihydrate
- 10 mg/mL Solution in Water (#H3570), iBlot PVDF membranes (# IB401031) were purchased
from ThermoFisher Scientific. FugeneHD transfection reagent (E2311) was purchased from
(Promega). Fetal Bovine Serum (FBS)–Heat Inactivated (#F4135), Bovine Serum Albumin
(#9048-46-8), Fibronectin (#F1141) were purchased from Millipore Sigma. cOmplete, Mini
Protease Inhibitor Tablets (#11836170001), PhosSTOP Phosphatase Inhibitor Cocktail Tablets
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(#04906837001) were purchased from Roche Applied Science. Recombinant Human EGF
Protein (#236-EG), Recombinant Human TGF-a Protein (#293-A) were purchased from R&D
Systems. Mini-PROTEAN® TGXTM Precast Gels (10% polyacrylamide) (#456-1036), ClarityTM
Western ECL reagents (#1705060) were purchased from Bio-Rad Laboratories, Inc.
Lactacystin, proteasome inhibitor (#ab141411) and Chloroquine diphosphate, apoptosis and
autophagy inhibitor (#ab142116) were purchased from AbCam. Tyrosine Kinase Inhibitors (TKIs)
Erlotinib HCl (OSI-744) (#S1023), Afatinib (BIBW2992) (#S1011), Osimertinib (AZD-9291)
(#S7297), Rociletinib (CO-1686) (#S7284), WZ4002 (#S1173), EAI045 (#S8242) were purchased
from Selleck Chemicals.
Cell culture. CHO-K1 cells (ATCC) were cultured in F12K Medium supplemented with 10%
FBS and Pen-Strep (100 I.U./mL penicillin and 100 mg/mL streptomycin) at 37°C in a CO2/air
(5%/95%) incubator. Cells were transfected using the TransIT-CHO Transfection Kit (Mirus Bio
LLC) (CHO-K1) or using FugeneHD (Promega), according to the manufacturer’s instructions.
Cell densities for all mammalian cell lines were determined with a Cellometer® Auto T4
automated counter. All cells were bona fide lines and periodically tested for mycoplasma with
DNA methods
Cloning and Mutagenesis. All EGFR DNA variants were cloned from a pcDNA3.1 plasmid,
generously donated by the Kuriyan Group (University of California, Berkeley), containing the
sequence of the full-length EGFR with an N-terminal FLAG tag [18,22]. Mutations were
introduced into the wild-type, CCH-1 and CCH-10 EGFR sequences using Quikchange
Lightning site-directed mutagenesis kit (Agilent Technologies), according to the manufacturer’s
instructions, with primers (purchased from Integrated DNA Technologies) listed in Table 3.1. All
DNA variants were ampliﬁed with XL-10 Gold Ultracompetent cells (Agilent Technologies).
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Bipartite Tetracysteine Display Assay i.e. Surface ReAsH Labeling Studies and Total
Internal Resonance Fluorescence (TIRF) Microscopy. ReAsH labeling was accomplished as
described previously [21,17] by treating CHO-K1 cells expressing EGFR variants with an
endocytosis inhibition cocktail (10 mM NaN3, 2 mM NaF, 5 mM 2-deoxy-D-glucose in F12-K
media) for 1 hr at 37oC. Cells were stimulated without/with 100 ng/mL of EGF (16.7 nM)) and
TGF-α

(16.7

nM)

prior

to

labeling.

Cells

were

washed

once

with

endocytosis

inhibitor-containing media before incubation with ReAsH labeling solution (2 mM ReAsH
(ThermoFisher Scientific), 20 mM BAL (Acros Organics) in F12K media) for 1 hr at 37oC. Cells
were washed and incubated with endocytosis inhibitor-containing F12K media supplemented
with 100 mM BAL for 10 min at 37oC. The media was removed, and cells ﬁxed using 4%
paraformaldehyde (PFA) in DPBS for 25 min at room temperature. Fixed cells were washed with
DPBS and blocked with 10% BSA in DPBS for 30 min at 37oC. Cells were then labeled with
primary antibody (mouse monoclonal mouse M2 anti-FLAG, 1:1000 dilution in 10% BSA in
DPBS) for 1 hr at 37oC, washed thrice with 10% BSA in DPBS, then incubated with secondary
antibody (AlexaFluor488- conjugated goat anti-mouse, 1:2000 dilution in 10% BSA in DPBS)
for 1 hr at 37oC. Cells were then washed twice with 10% BSA in DPBS, washed once with
DPBS, then nuclear-stained with Hoescht 33342 (1.62 mM in DPBS) for 5 min at 37oC. Cells
were then washed once with DPBS and stored in DPBS at 4oC, prior to imaging. Labeled cells
were monitored via TIRF microscopy, conducted on a Leica microsystems AM TIRF MC
DMI6000B ﬁtted with an EM-CCD camera (Hamamatsu) with HCX PL APO 63x/1.47 oil
corrective objectives, as described previously[17,21]. Images were analyzed with ImageJ (FIJI)
as described previously[17,21].
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Immunofluorescent labeling, confocal microscopy and Image analysis.
Immunofluorescent labeling and confocal microscopy to assess localization of EGFR variants
expressed in CHO-K1 cells was carried out as described previously[30] with slight modification.
CHO-K1 cells expressing FLAG-tagged EGFR variants were incubated without/with 100 ng/mL
of EGF (16.7 nM) or TGF-α (16.7 nM) for 1 hr at 4oC to allow growth factor binding. For
experiments with TKIs, instead of growth factor treatment, cells were incubated with 10uM TKI
(as indicated) in F12K medium at 4oC to allow TKI binding. Cells were then washed with DPBS
and incubated with serum free media at 37oC for 8 or 40 minutes as indicated to allow
endocytosis. Cells were then fixed using 4% PFA in DPBS for 25 min at room temperature.
Cells were washed with DPBS and incubated with blocking buffer (5% normal goat serum
(CST), 0.3% Triton X-100 in DPBS) for 1 hr at 37oC. Cells were then labeled with indicated
primary antibodies overnight (~12 hrs) at 4oC (mouse M2 anti-Flag, 1:1000 dilution and rabbit
anti-Rab7, 1:1000 dilution or rabbit anti-EEA1, 1:1000 dilution or rabbit anti-Rab11, 1:1000
dilution in antibody dilution buffer (1% BSA, 0.3 % Triton X-100 in DPBS)). Cells were then
washed thrice with DPBS and incubated with secondary antibody (AlexaFluor488- conjugated
goat anti-rabbit, 1:500 dilution or AlexaFluor555- conjugated goat anti-mouse, 1:500 dilution in
antibody dilution buffer) for 2 hr at room temperature. Cells were then washed twice with DPBS
and nuclear-stained with Hoescht 33342 (1.62 mM in DPBS) for 5 min at room temperature.
Cells were then washed once with DPBS and stored in DPBS at 4oC, prior to imaging.
Laser-scanning confocal microscopy experiments of labeled immunofluorescent samples were
performed at room temperature on an inverted Zeiss LSM 880 laser-scanning confocal
microscope equipped with a Plan-Apochromat ×63/1.4 numerical aperture oil immersion lens
and a diode 405 nm laser, an Argon 458, 488, 514 nm laser, a diode pumped solid-state 561
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nm laser and a 633 nm HeNe laser with standard settings. DAPI and Alexa-488, Alexa Fluor
555, and Alexa Fluor 647 dyes were excited with 405-, 488-, 546-, and 633-nm laser lines, and
emitted light was collected through band pass filters transmitting wavelengths of 420–480 nm,
505–530 nm and 560–615 nm and a long-pass filter transmitting 615 nm, respectively. The
pinhole size was set to 1 airy unit. Images were acquired at a nuclear section with fixed
thresholds. Image acquisition was performed with ZEN software (Carl Zeiss). Raw images were
exported as .lsm files. Images were analyzed using ImageJ software[125]. Colocalization of
EGFR with indicated endocytic marker (Rab7, Rab11, EEA1) was evaluated as Manders’
Colocalization Coefficient (MCC)[156] which represents the sum of intensities of green pixels
(due to Rab11 or Rab7 or EEA1) that also contain red (due to FLAG-tagged EGFR) divided by
the total sum of green intensities. Colocalization was evaluated using JACoP (Just Another
Colocalization Plugin)[157] in ImageJ. MCC values for each condition obtained from multiple
cells collected over at least 2 biological replicates were pooled and represented as Mean with
S.E.M using Prism 8.4.3
Western Blot Analysis of EGFR Expression and Autophosphorylation. Western blot analysis
of EGFR expression and autophosphorylation in transfected CHO-K1 cells was accomplished
as described previously with slight modification [17,21]. CHO-K1 cells expressing FLAG-tagged
EGFR variants were serum starved overnight (~12 hours). 48 hr post seeding cells were
stimulated without/with 100 ng/mL of EGF (16.7 nM) or TGF-α (16.7 nM) for 5 min at 37oC,
washed with serum free F12K media, and lysed in 100 mL of lysis buffer (50 mM Tris,150 mM
NaCl, 1 mM EDTA, 1 mM NaF, 1% Triton X-100, pH 7.5, 1x cOmplete protease inhibitor
cocktail, 1x Phos-Stop) for 1 hr. For experiments investigating the time dependent changes in
intracellular EGFR levels, CHO-K1 cells were incubated without/with 100 ng/mL of EGF (16.7
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nM) or TGF-α (16.7 nM) for 15 min following which, growth factor solution was washed with
DPBS and cells were incubated at 37oC with serum free media for 0-90 minutes and cell lysis
was carried out as described previously. For experiments investigating the time dependent
changes in EGFR phosphorylation, CHO-K1 cells were incubated without/with 100 ng/mL of
EGF (16.7 nM) or TGF-α (16.7 nM) for 15 min following which, growth factor solution was
washed with DPBS and cells were incubated at 37oC with serum free media for 0-8 minutes
and cell lysis was carried out as described previously. Clariﬁed cell lysates were subjected to
reducing 4-15% polyacrylamide SDS-PAGE electrophoresis and transferred to immuno-blot
PVDF membranes. Membranes were blocked with 5% milk in TBS-T Buffer (50 mM Tris, 150
mM NaCl, 0.1% Tween, pH 7.4) for 1 hr followed by an overnight incubation at 4oC of indicated
primary (rabbit or mouse) antibodies. Blots were washed with TBS-T and incubated with either
anti-rabbit or anti-mouse goat horseradish peroxidase conjugate secondary antibodies for 1 hr
at room temperature, then washed with TBS-T. Blots were then visualized using Clarity Western
ECL reagents on a ChemiDoc XRS+/ ChemiDocMP instrument, and intensities of
immuno-stained bands measured with ImageJ 64[125]. When assessing phosphorylation of
EGFR/ gel loading at multiple positions using the same samples, the blots obtained with a
given phospho-EGFR antibody were stripped with Restore Western Blot Stripping Buffer/ and
antibody stripping buffer (Tris-HCl (62.5 mM), SDS (2%w/v), 2-mercaptoethanol (0.7%v/v)) and
re-probed with a different phospho-EGFR antibody. For experiments investigating the time
dependent changes in intracellular EGFR levels, the FLAG signal (total EGFR) was normalized
to the vinculin loading control and normalized signal for the condition without any growth
factor/ inhibitor treatment. For experiments investigating the time dependent changes in EGFR
phosphorylation, the phospho-EGFR signal (pY1045, pY1068, pY1173) was normalized to the

64

total EGFR (FLAG signal) and vinculin/ tubulin was used as a loading control. For western blot
experiments with the tyrosine kinase inhibitors (TKI), CHO-K1 cells expressing L834R/ T766M
EGFR were pre-treated with serum free F12K medium containing 10uM of TKI at 37oC for 30
minutes, washed once with DPBS followed by incubation with serum free DMEM for 12 hrs,
prior to cell lysis. FLAG, pY1045 and pY1068 signal was normalized to the vinculin loading
control and corresponding signal detected at 12 hours without inhibitor/ TKI treatment. For all
experiments with proteasomal/ lysosomal inhibitors, the experiments were carried out with
CHO-K1 cells as described before in the methods, involving a pretreatment with 10uM
Lactacystin or 100uM Chloroquine for 1 hr at 37oC prior to growth factor or TKI treatment.

Table 3.1. List of mutagenesis primers used to design JM decoupling mutants
EGFR Target Mutation

Primer sequence (5’-3’)

E661R

forward: 5’- ggaggctgctgcagaggagggagcttgtgg -3’
reverse: 5’- ccacaagctccctcctctgcagcagcctcc -3’

K652A/ R656A (or KRAA)

forward: 5’- cacatcgttcgggcgcgcacgctggcgaggctgctgca -3’
reverse: 5’- tgcagcagcctcgccagcgtgcgcgcccgaacgatgtg -3’

T654D

forward: 5’- gcagcagcctccgcagatcgcgcttccgaacgatg -3’
reverse: 5’- catcgttcggaagcgcgatctgcggaggctgctgc -3’
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Figure. 3.1. Design of E661R and KRAA EGFR decoupling mutants. (A) Helical wheel
diagrams illustrating relative positions of residues within the N-terminal region of the EGFR JM
segment of WT, E661R, and KRAA EGFR when assembled into an EGF-type (left) or
TGF-α-type (right) coiled-coil. Bold red lines identify potential salt bridge interactions referred to
in the text. (B) Representative TIRF-M images of CHO-K1 cells illustrating ReAsH labeling (red
fluorescence) and expression (green fluorescence) of FLAG-tagged CCH-1 and CCH-10 variants
of WT, E661R, or KRAA EGFR with or without EGF or TGF-α stimulation (16.7 nM). Scale bars =
10 µm. (C) Bar plots illustrating the fold increase in expression-corrected ReAsH fluorescence
over background. n = # of cells. Error bars = s.e.m. ****p<0.0001, ***p<0.001, **p<0.01, *p<0.1
from one-way ANOVA with Bonferroni post-analysis accounting for multiple comparisons. n.s.,
not significant.
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Figure 3.2.: Design of EGFR decoupling mutants (KRAA, E661R) and controls (T654D) and
TIRF microscopy images and western blots related to Bipartite tetracysteine display
experiments. (A) Influencing coiled coil preferences by design. In WT EGFR, both coiled coil
conformations are energetically accessible, and the identity of the bound growth factor
influences which conformation is adopted. In Mutant 1, the EGF-type coiled coil is destabilized
and the TGF-α-type structure is favored; in Mutant 2, the TGF-α-type coiled coil is destabilized
and the EGF-type structure is favored. (B) Domain diagram of FLAG-tagged EGFR illustrating
sequences of WT EGFR as well as E661R and KRAA decoupling mutants that favor the
EGF-type or TGF-α-type coiled coil, respectively; T654D EGFR also contains a mutation within
the JM but at a location predicted to not affect relative coiled coil stability (light blue box).
E661R, KRAA, and T654D EGFR respond like WT EGFR to growth factor stimulation.
Representative western blots illustrating expression and extent of Y1173, Y1086, and Y1068
phosphorylation of (C) FLAG-tagged WT, E661R, KRAA, and T654D EGFR and (D)
FLAG-tagged CCH-1 and CCH-10 variants of WT, E661R, KRAA, and T654D EGFR in CHO-K1
cells stimulated continuously without/with EGF and TGF-α (16.7 nM) for 5 minutes 37oC.
Alpha-tubulin is used as loading control. (E) Representative TIRF-M images of CHO-K1 cells
illustrating ReAsH labeling (red fluorescence) and expression (green fluorescence) of
FLAG-tagged CCH-1 and CCH-10 variants of T654D without/ with EGF/ TGF-α stimulation (16.7
nM). Scale bars = 10 µm. (F) Bar plots illustrating the quantification of TIRF-M results from ‘n’
cells expressing FLAG-tagged T654D EGFR as fold increase in expression-corrected ReAsH
fluorescence over background. Error bars = s.e.m. ****p<0.0001, n.s. p>0.05 from one-way
ANOVA with Dunnett’s post-analysis accounting for comparisons within individual mutants to
no growth factor treated control. n.s., not significant. Scale bars = 10 µm.
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Figure 3.3. FLAG-tagged WT, E661R, and KRAA EGFR colocalize with EEA1 and not with
Rab7 or Rab11 respectively, 8 minutes after stimulation with EGF or TGF-α. (A, C, E)
Representative confocal microscopy images of CHO-K1 cells expressing FLAG-tagged WT,
E661R, KRAA and T654D EGFR (false-colored red) 8 minutes after stimulation with EGF or
TGF-α (16.7 nM). (A) Early endosomes (false-colored green) are identified using anti-EEA1
antibody. (C) Degradative endosomes (false-colored green) are identified using an anti-Rab7
antibody. (E) Recycling endosomes (false-colored green) are identified using an anti-Rab11
antibody. (A, C, E) Scale bars = 10 µm. Bar plots illustrating the quantified Mander’s
co-localization coefficient (MCC) values of FLAG-tagged WT, E661R, KRAA and T654D EGFR
with (B) EEA1 (D) Rab7 (F) Rab11 8 minutes after stimulation with EGF/ TGF-α (16.7 nM) for ‘n’
cells. Error bars, s.e.m., n.s. not-significant from one-way ANOVA with Tukey’s multiple
comparison test.
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Figure 3.4. The path of EGFR trafficking in CHO-K1 cells is controlled by JM coiled coil
identity. Confocal microscopy of CHO-K1 cells expressing FLAG-tagged WT, E661R, or KRAA
EGFR (false colored red), immuno-labeled with (A) Rab7 (false colored green) as a marker for
degradative endosomes or (B) Rab11 (false colored green) as a marker for recycling
endosomes, 40 minutes after stimulation with EGF (E) or TGF-α (T). Scale bars = 10 µm. (C)
Bar plots illustrating the Manders colocalization coefficient (MCC) of FLAG-tagged WT, E661R
and KRAA EGFR with either Rab7 or Rab11 40 minutes after stimulation with EGF/TGF-α. n = #
of cells. Error bars = s.e.m. ****p<0.0001, ***p<0.001, **p<0.01, *p<0.1, n.s. not significant, from
one-way ANOVA with Tukey’s multiple comparison test.
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Figure 3.5. Co-localization of FLAG-tagged WT, E661R, KRAA and T654D EGFR with
EEA1, 40 minutes after stimulation with EGF/TGF-α and co-localization of FLAG-tagged
T654D EGFR with Rab7, Rab11, 40 minutes after stimulation with EGF/TGF-α. (A)
Representative confocal microscopy images of CHO-K1 cells expressing FLAG-tagged WT,
E661R, KRAA and T654D EGFR (false colored red) 40 minutes after stimulation with EGF or
TGF-α (16.7 nM). Early endosomes (false colored green) are identified using an anti-EEA1
antibody. Scale bars = 10 µm. (B) Bar plots illustrating the quantified MCC values of
FLAG-tagged WT, E661R, KRAA and T654D EGFR with EEA1 40 minutes after stimulation with
EGF or TGF-α (16.7 nM) for ‘n’ cells. Error bars, s.e.m., n.s. not significant from one-way
ANOVA with Tukey’s multiple comparison test. (C, D) Confocal microscopy of CHO-K1 cells
expressing FLAG-tagged T654D EGFR (false-colored red) 40 minutes after stimulation with
EGF/ TGF-α. (C) Degradative endosomes are identified using an anti-Rab7 antibody
(false-colored green). (D) Recycling endosomes are identified using an anti-Rab11 antibody
(false-colored green). Scale bars = 10 µm. Bar plots illustrating the quantified MCC values of
FLAG-tagged T654D (green) with either (C) Rab7 or (D) Rab11 40 minutes after stimulation with
EGF or TGF-α (16.7 nM) for ‘n’ cells. Error bars, s.e.m. ****p<0.0001, *p<0.1, from t-test.
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Figure 3.6. Time dependent decay in phosphorylation of FLAG-tagged WT, E661R, KRAA
and T654D EGFR at Y1045, Y1068, Y1173. Immunoblots illustrating the time-dependent
change in (A) pY1045; (B) pY1068; and (C) pY1173 0-8 minutes after stimulation with EGF or
TGF-α (16.7 nM). FLAG blot indicates levels of total EGFR. Vinculin is used as a loading control.
Blots represent data pooled from at least 3 biological replicates and densitometric
quantification of signal pYEGFR/ FLAG (Mean and S.E.M.) is included below the immunoblots.
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Figure 3.7. Co-localization of FLAG-tagged G628A, G628F, and G628V EGFR with EEA1 (8
and 40 min) and Rab7 or Rab11 (8 min) after stimulation with EGF or TGF-α.
Representative confocal microscopy images of CHO-K1 cells expressing FLAG-tagged WT,
G628A, G628F, and G628V EGFR (false colored red) stimulated for (A, C, E) 8 minutes; and (G)
40 minutes with EGF/ TGF-α (16.7 nM). (A, G) Early endosomes (false-colored green) are
identified using an anti-EEA1 antibody. (C) Degradative endosomes (false-colored green) are
identified using an anti-Rab7 antibody. (E) Recycling endosomes (false-colored green) are
identified using an anti-Rab11 antibody. (A, C, E, G) Scale bars = 10 µm. Bar plots illustrating
the quantified MCC values of FLAG-tagged WT, G628A, G628F, G628V EGFR with (B) EEA1 or
(D) Rab7 or (F) Rab11, 8 min or (H) EEA1, 40 min; after stimulation with EGF/ TGF-α (16.7 nM)
for ‘n’ cells. Error bars, s.e.m., n.s. not significant from one-way ANOVA with Tukey’s multiple
comparison test.
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Figure 3.8. Point mutations within the EGFR transmembrane helix allosterically influence
the pathway of receptor trafficking. Confocal microscopy of CHO-K1 cells expressing
FLAG-tagged G628A, G628F and G628V EGFR (false colored red) and immuno-labeled with (A)
Rab7 (false colored green) as a marker for degradative endosomes or (B) Rab11 (false colored
green) as a marker for recycling endosomes, 40 minutes after stimulation with EGF (E) or TGF-α
(T). Scale bars = 10 µm. (C) Bar Plots illustrating colocalization of FLAG-tagged G628A, G628F
and G628V EGFR with either Rab7 or Rab11-GFP 40 minutes after stimulation with EGF/TGF-α
(16.7 nM). n = # of cells. Error bars = s.e.m.. ****p<0.0001, ***p<0.001, **p<0.01, *p<0.1, n.s.
not significant from one-way ANOVA with Tukey’s multiple comparison test.
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Figure 3.9. Time dependent decay in phosphorylation of FLAG-tagged WT, G628A, G628F
and G628V EGFR at Y1045, Y1068, Y1173. Immunoblots illustrating the time-dependent
change in (a) pY1045; (b) pY1068; and (c) pY1173 for FLAG-tagged WT EGFR, G628A, G628F
and G628V 0-8 minutes after stimulation with EGF or TGF-α (16.7 nM). FLAG blot indicates
levels of total EGFR. Vinculin/ Alpha-Tubulin is used as a loading control. Blots represent data
pooled from at least 3 biological replicates and densitometric quantification of pYEGFR/FLAG
signal (Mean and S.E.M.) is included below the immunoblots.
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Figure 3.10.. Coiled coil control of EGFR degradation. (A) Immunoblots illustrating the level
of FLAG-tagged WT, G628A, G628F, and G628V EGFR detected in CHO-K1 cells 90 minutes
after stimulation with or without EGF/TGF-α (16.7 nM) and without/with pre-incubation with the
lysosomal inhibitor chloroquine, C (100 µM) [158] or the proteasomal inhibitor lactacystin, L (10
µM)[159] for 1 hour at 37 oC. (B) Plot illustrating the normalized percent of intact FLAG-tagged
WT, G628A, G628F, and G628V EGFR as shown in 3.10.A. Vinculin is used as loading control.
Error bars = s.e.m.. ****p<0.0001, ***p<0.001, **p<0.01, *p<0.1, n.s. not significant from
one-way ANOVA with Dunnett’s multiple comparison test.
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Figure 3.11. Clinically relevant, third-generation tyrosine kinase inhibitors influence
L834R/T766M EGFR trafficking and induce EGFR degradation. Confocal microscopy of
CHO-K1 cells expressing FLAG-tagged L834R/T766M EGFR (false colored red) and and
immuno-labeled with (A) Rab7 (false colored green) as a marker for degradative endosomes or
(C) Rab11 (false colored green) as a marker for recycling endosomes, 30 minutes after
pre-incubation without/with 10 μM of indicated TKI. Scale bars = 10 µm. Bar plots illustrating
the MCC value representing the colocalization of FLAG-tagged L834R/T766M EGFR with (B)
Rab7 or (D) Rab11 without/with the indicated TKI. n = # of cells. Error bars = s.e.m.
****p<0.0001, ***p<0.001, **p<0.01, *p<0.1, n.s. not significant, from one-way ANOVA with
Tukey’s multiple comparison test. (E) Normalized loss of FLAG-tagged L834R/T766M EGFR in
CHO-K1 cells 12 hours following pre-incubation without/with 100 µM chloroquine (C) or
lactacystin (L) (10 µM) and/or 10 µM Erlotinib (Er), afatinib (Af), AZD9291 (AZ), CO-1686 (CO),
WZ-4002 (WZ), or EAI045 (EA). Phosphorylation of L834R/T766M EGFR at (F) Y1045; and (G)
Y1068 in CHO-K1 cell lysates prepared as described in 3.11.E. In 3.11. E, F, G, Error bars =
s.e.m.. ****p<0.0001, ***p<0.001, **p<0.01, *p<0.1, n.s. not significant from one-way ANOVA
with Dunnett’s multiple comparison test.
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Figure 3.12. Immunoblots illustrating the intracellular levels of FLAG-tagged and
phosphorylated EGFR detected at various time points post treatment with EGFR TKIs (A)
Immunoblots illustrating the cellular expression (FLAG) and dose-dependent phosphorylation of
FLAG-tagged L858R/T790M EGFR at Y1045, detected in CHO-K1 cells 30 minutes following
pre-incubation without/ with 10, 1.0, 0.1 and 0.01 uM of TKIs erlotinib (+Er), afatinib, AZD9291,
CO-1686, WZ-4002 and EAI045. Alpha-tubulin is used as loading control. (B) Immunoblots
illustrating the loss of FLAG-tagged L834R/T766M EGFR detected in CHO-K1 cells lysed 12
hours following pre-incubation without/with 100 µM chloroquine, C or lactacystin, L (10 µM) for
1 hour followed by pre-incubation without/with 10 µM erlotinib, afatinib, AZD9291, CO-1686,
WZ-4002, or EAI045. Immunoblots illustrating the phosphorylation of L834R/T766M EGFR at
(C) Y1045; and (D) Y1068 in CHO-K1 cell lysates prepared as described in 3.12.C. Vinculin is
used as loading control.
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Chapter 4. Summary and Analysis of partially completed projects and future directions
This chapter describes preliminary experiments that were performed on two projects that were
initiated in the early and later parts of Ph.D. research. The aim of the first project was to
investigate the role of receptor multimerization on the JM structure of EGFR. This work was
performed with Dr. Amy E. Doerner. The aim of the second ongoing project is to investigate the
effect of JM structure on the interactome of WT and oncogenic EGFR using APEX2-based
proximity labeling and mass spectrometry. This work has been performed with Sol H.-H. Chang.
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Chapter 4. Summary and Analysis of partially completed projects and future directions.
4.1. Investigating the role of receptor multimerization on the JM structure of EGFR. In the
canonical view of growth factor induced EGFR activation, the receptor transitions from an
equilibrium between an inactive monomeric structure and inactive dimeric structure to active
dimeric structure [6,160]. High resolution structures of the ECD [12,13,23,45,122], TM [15,18],
JM [15,18] and Kinase [22] domains reveal that in its active dimeric structure, dimerization of
the monomeric units is mediated by interactions arising from all four of these domains. In
addition to forming active dimeric structures, there is also evidence that EGFR can assemble
into catalytically competent higher order oligomers in cells [161–163]. More recently, two
independent studies from the Kuriyan [164] and Shaw/ Fernandez [165] research groups have
illuminated structural details for the mechanisms by which receptor oligomerization may occur.
In the study from the Kuriyan lab, Huang and colleagues used single molecule imaging
combined with photobleaching experiments in Xenopus oocytes to observe clustering of
fluorescently labeled particles of EGFR [164]. In their studies they found that following
treatment with EGF, fluorescently labeled EGFR particles appear as clusters on the surface of
Xenopus cells [164]. To characterize the number of particles present in individual clusters, the
authors used photobleaching experiments to sequentially bleach out fluorescence arising from
individual fluorescently labeled EGFR particles within a cluster in a field of view. The authors
observed that for nearly 50% of these clusters complete photobleaching would occur following
a multi-step photobleaching procedure, which the authors suggested was on account of
receptor oligomerization (as opposed to photobleaching in a single step (25%) observed for
monomers or in two steps (25%) for dimers) [164]. To characterize the surface of EGFR used
for the assembly of these oligomers the authors used a combination of structural modeling and
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mutagenesis studies in combination with these single molecule photobleaching experiments.
From their studies, the authors determined that oligomerization is primarily mediated by
interactions arising from the domain IV of the EGFR ECD [164]. The authors identified multiple
combinations of domain IV mutations that were demonstrated via single molecule
photobleaching experiments to inhibit multimerization of EGFR – (i) I544K/ I556K/ I562R/ V592E
dubbed IIIV/KKRE; (ii) V526E/ E527R/ N528R dubbed VEN/ERR; (iii) T548N/ N554R – and a
domain IV control mutant mutant I544A/ I556A/ I562R/ V592E dubbed IIIV/AARE that did not
inhibit multimerization [164].
In the Schepartz lab, the focus of research has been to study how chemical information
encoded by diverse growth factors is communicated through the allosteric network of EGFR to
mediate diverse signaling outcomes [17,20,21]. The focus of this research has been the JM
region that plays a critical role in diverse aspects of EGFR biology. Work in the Schepartz lab
has demonstrated that upon activation by growth factors, the JM-A of EGFR can assemble into
distinct coiled coil conformations that allosterically encode growth factor identity and are
necessary and sufficient for modulating intracellular EGFR biology [17,20,21]. In this particular
project, my efforts were focused towards exploring whether inhibiting EGFR multimerization
had any effect on altering the allosteric network that communicates growth factor identity in
terms of affecting the JM-A coiled coil structure.
To investigate the effect of inhibiting multimerization [164] on the JM-A structure of growth
factor activated EGFR, we made use of bipartite tetracysteine display [39,40]. For our
experiments, we cloned CysCys containing (CCH-1 and CCH-10) versions of the EGFR variants
that were reported to inhibit multimerization (IIIV/KKRE, VEN/ERR, TN/RR) or not (IIIV/AARE);
CCH-1 and CCH-10 variants probe for the assembly of EGF-type or TGF-ɑ-type JM-A coiled
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coil respectively [17,20,21]. In control experiments I was able to verify that all the CCH-1
variants namely IIIV/KKRE-CCH-1, VEN/ERR-CCH-1, TN/RR-CCH-1 and IIIV/AARE-CCH-1 were
all expressed in CHO-K1 cells and responded to treatment with saturating concentrations
(16.7nM) of EGF/ TGF-ɑ (phosphorylation at Y1173/ Y1068 and Erk phosphorylation) analogous
to the WT-CCH-1 variant (Figure 4.1. C).
In the bipartite tetracysteine display experiments, CHO-K1 cells expressing IIIV/KKRE-CCH-1,
VEN/ERR-CCH-1, TN/RR-CCH-1 and IIIV/AARE-CCH-1 or WT-CCH-1 were stimulated with
growth factor (or not), incubated with ReAsH, washed, and immuno-stained. Receptor
expression was monitored using a fluorescently labeled antibody to an N-terminal FLAG
epitope. Using TIRF microscopy, the level of both cell surface ReAsH fluorescence (red) and
EGFR expression (green) was quantified across multiple cells (40-109) expressing either EGFR
or EGFRvIII variants. The cell-surface ReAsH fluorescence detected (over background) was
normalized to the surface EGFR-expression detected (over background) to calculate the
fold-increase in ReAsH fluorescence [17,20,21] (Figure 4.1.A,B). Cells expressing WT-CCH-1
displayed levels of normalized ReAsH fluorescence relative to background that mirrored
previous reports (1.76 ± 0.13 with EGF treatment; 1.21 ± 0.05 with TGF-ɑ) [17,20,21] (Figure
4.1.A,B). In an analogous manner the other four EGFR variants also showed an almost 2-fold
increase in normalized ReAsH fluorescence relative to background only when treated with EGF
(IIIV/AARE-CCH-1: 1.80 ± 0.14; IIIV/KKRE-CCH-1: 2.10 ± 0.13; VEN/ERR-CCH-1: 2.30 ± 0.19;
TN/RR-CCH-1:

2.33

±

0.13) and

not

with

TGF-α

(IIIV/AARE-CCH-1:

1.20

±

0.11;

IIIV/KKRE-CCH-1: 1.25 ± 0.09; VEN/ERR-CCH-1: 1.45 ± 0.11; TN/RR-CCH-1: 1.26 ± 0.09)
(Figure 4.1.A,B). The results of my initial experiments suggest that inhibiting multimerization
does not have any obvious effect on assembly of the EGF-type structure. Future experiments
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would need to evaluate (i) whether or not inhibiting multimerization affects the TGF-α-type
structure and (ii) that the multimerization phenotype of the variants IIIV/AARE, IIIV/KKRE,
VEN/ERR, TN/RR is not affected by the incorporation of cysteine residues to generate the
CCH-1/ CCH-10 versions of these constructs.
4.2. Efforts towards understanding the effect of JM structure on the interactome of EGFR
using APEX2-based proximity labeling and mass spectrometry.
Rationale: A research direction that directly follows from my work discussed in Chapter 3 is to
elucidate the mechanism by which alternate JM-A coiled coil structures modulate EGFR
biology. In chapter 3 we hypothesized that differences in EGFR biology may result partly from
the altered patterns of EGFR C-tail phosphorylation that is responsible for recruiting diverse
intracellular down regulatory mechanisms (Figure 4.2.A). While this hypothesis can explain the
observed biological effects with WT EGFR, they are insufficient for explaining the observations
with oncogenic L834R/ T766M EGFR treated with different classes of TKI. In this latter case,
we observed that treatment with the different classes of TKI lead to differences in the biology of
L834R/ T766M EGFR in a manner that is independent of C-tail phosphorylation but correlates
directly with JM-A coiled coil structure. This suggests that additional down-regulatory
mechanisms that are dependent on JM-A structure may be involved. It is possible that the
assembly of the alternate JM-A coiled coil structures can directly alter the interactome of EGFR
between the two states (Figure 4.2.B). In order to probe those differences in interactome, we
would need to use a robust methodology to isolate and reliably characterize the protein
partners of EGFR in the different coiled coil states using mass spectroscopy. Mass
spectrometric methods have been previously used to characterize the interacting partners
EGFR following activation with growth factors EGF and TGF-α [30,166,167]. Proximity labeling
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using the engineered peroxidase APEX2 and mass spectrometric characterization is a robust
methodology for detecting protein protein interactions and spatiotemporally resolving
interaction networks in mammalian cells [168–171]. Here we propose to use a an
APEX2-based proximity labeling followed mass spectrometric characterization strategy to
isolate and identify the interacting partners of (i) WT EGFR and G628F-EGFR or G628V EGFR
that fix the JM-A coiled coil structure into the EGF-type or TGF-α-structure respectively and (ii)
L834R/ T766M EGFR treated with different TKIs classes (Figure 4.2.C).
Approach and preliminary results: For our proximity labeling/ MS experiment workflow, we
first generated fusions of the engineered peroxidase APEX2 with (i) WT EGFR (ii) JM decoupling
mutants: G628A-EGFR, G628F-EGFR and G628V-EGFR (iii) L834R/ T766M EGFR. Mammalian
cells expressing these fusion constructs would be treated with biotin-phenol followed by either
(i) activation with EGFR specific growth factors EGF or TGF-α or (ii) inhibition with L834R/
T766M EGFR-specific TKIs. Thereafter the cells would be treated with H2O2 to initiate the rapid
biotinylation reaction after specific periods of time (0-8 min: to identify for early interactors;
40-90min: to identify to later interactors). Cells would be subsequently lysed and the
biotinylated proteins (by virtue of their interaction to EGFR and thus APEX2) will be purified and
enriched for using streptavidin pulldown. Thereafter, the isolated proteins would be identified
using LC-MS/MS and mapping onto the mammalian cell proteome.
In this section I describe my efforts in preliminary experiments to ensure that EGFR-APEX2 (i)
was expressed in CHO-K1 mammalian cells (ii) had growth factor dependent autophosphorylation activity comparable to WT EGFR (that did not bear an APEX2 fusion) (iii) had
APEX-2 enzymatic activity comparable to APEX2 (that was not fused to EGFR). The proximity
labeling/ MS experiments will be carried out by fellow graduate student Sol Chang. For these
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initial experiments in addition to WT EGFR, EGFR-APEX2 and APEX2, we designed two
additional control constructs K721M-EGFR (where EGFR kinase activity is abrogated) and
D208N APEX2 (where APEX2 peroxidase activity is abrogated) (Figure 4.3.A). We first sought
to evaluate the expression and activity of EGFR-APEX2 in CHO-K1 cells. CHO-K1 cells were
transiently transfected with FLAG-tagged WT-EGFR, EGFR-APEX2, APEX-2, K721M-EGFR and
D208N APEX2. Using western blot assays we probed for the expression of the FLAG-tagged
variants using an anti-FLAG antibody. We observed that all FLAG-tagged variants were
expressed in CHO-K1 cells (Figure 4.3.B-D). We next sought to evaluate the growth factor
dependent auto-phosphorylation activity of WT EGFR-APEX2. CHO-K1 cells expressing
FLAG-tagged WT EGFR, EGFR-APEX2 and a negative control K721M-EGFR were treated with
saturating amounts (16.7 nM) of EGF/ TGF-α). Using western blot analysis we evaluated the
auto-phosphorylation activity of the FLAG-tagged EGFR variants at C-tail tyrosine residues
Y1045 and Y1068 (Figure 4.3. C-F). As expected, WT EGFR was robustly phosphorylated at
both Y1045 (Figure 4.3. C,E) and Y1068 (Figure 4.3. D,F) following treatment with either EGF
or TGF-α (and not in the absence of growth factor treatment). In an analogous fashion
EGFR-APEX2 was phosphorylated at both Y1045 (Figure 4.3. C,E) and Y1068 (Figure 4.3. D,F)
following treatment with both EGF or TGF-α at levels comparable to WT EGFR. With K721M
EGFR no auto-phosphorylation activity was detected at either tyrosine residues both in the
absence and presence of EGF or TGF-α. Overall we observed that the fusion of APEX2 to WT
EGFR did not significantly affect its growth factor dependent phosphorylation at C-tail residues
Y1045 and Y1068 (Figure 4.3. C-F). We next sought to evaluate the peroxidase activity of
EGFR-APEX2. For this we used a fluorescence based assay that makes use of the peroxidase
mediated conversion of Amplex red to Resorufin [168]. Amplex red that is ambiently non
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fluorescent, upon treatment with H2O2 and peroxidase (in this case APEX2) is spontaneously
converted to brightly fluorescent dye resorufin. The time dependent change in fluorescence
provides a robust and instantaneous readout of the enzymatic activity of the peroxidase
enzyme (APEX2) (Figure 4.3.G). Clarified cellular lysates from CHO-K1 cells expressing
APEX-2, EGFR-APEX2 and a negative control D208N APEX2 were diluted in DPBS and treated
individually with H2O2 and Amplex Red. Immediately following H2O2 and Amplex Red addition,
the resulting fluorescence of the reaction mixture was recorded at regular time intervals. From
the time dependent changes in fluorescence, the activity of the APEX2 constructs was
evaluated. From our experiments, we observed that both APEX2 and EGFR-APEX2 were
active, albeit the activity of EGFR-APEX2 was both slightly lesser and slightly slower as
compared to APEX2 (Figure 4.3.H). No detectable peroxidase activity was observed with the
negative control D208N APEX2 (where peroxidase activity is abrogated) (Figure 4.3.H). Overall
we observe that although APEX2 fused to EGFR with a flexible GGS linker retains considerable
enzymatic activity, its extent and velocity is slightly reduced (Figure 4.3.H). Given that the
proper enzymatic activity of APEX2 in the fusion construct is critical for the subsequent
proximity labeling experiments, it may be worthwhile to investigate if extending the flexible
linker between EGFR and APEX2 restores the enzymatic activity of APEX2 to level comparable
to APEX2. Nonetheless, it is encouraging that the EGFR-APEX2 fusion is expressed in
mammalian cells and retains enzymatic activity both in the EGFR and APEX2 parts. I am
excited to see how this project develops in the future and what all we learn about the
interactome of EGFR when its JM is fixed either by mutations in the TM or treatment with TKIs.
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4.3. Materials and Methods
Materials. Antibodies. Goat polyclonal anti-Rabbit, Horseradish Peroxidase (HRP)-conjugated
(#7074),

Goat

polyclonal

anti-Mouse,

HRP-conjugated

(#7076),

Rabbit

monoclonal

anti-Phospho-EGF ReceptorTyr1173, (53A5) (#4407), Rabbit polyclonal anti-Phospho-EGF
Receptor Tyr1086 (#2220), Rabbit polyclonal anti-Phospho-EGF Receptor Tyr1068 (#2234),
Rabbit

polyclonal

anti-Phospho-EGF

Receptor

Tyr1045

(#2237),

Rabbit

monoclonal

anti-α-Tubulin (#2125) were purchased from Cell Signaling Technologies (CST). Mouse
monoclonal (M2) anti-Flag (#F1804), was purchased from Millipore Sigma. Goat anti-Mouse IgG
(H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 488®-conjugate (#A11001), was
purchased from ThermoFisher Scientific.
Chemicals and Recombinant Proteins. F-12K Medium (#10-025-CV), Dulbecco’s Phosphate
Buffered Saline (DPBS) (#14190), Fetal Bovine Serum (FBS)–Heat Inactivated (#11082147),
Penicillin/Streptomycin (#1514012), Non-enzymatic Cell Dissociation Solution (#13151014),
RestoreTM Western Blot Stripping Buffer (#21059), Hoechst 33342, Trihydrochloride, Trihydrate
10 mg/mL Solution in Water (#H3570), iBlot PVDF membranes (# IB401031), Amplex Red
Hydrogen Peroxide/Peroxidase Assay Kit (A22188) were purchased from ThermoFisher
Scientific. TransIT-CHO transfection kit was purchased from Mirus Bio LLC. Fetal Bovine Serum
(FBS)–Heat Inactivated (#F4135), Bovine Serum Albumin (#9048-46-8), Fibronectin (#F1141)
were

purchased

from

Millipore

Sigma.

cOmplete,

Mini

Protease

Inhibitor

Tablets

(#11836170001), PhosSTOP Phosphatase Inhibitor Cocktail Tablets (#04906837001) were
purchased from Roche Applied Science. Recombinant Human EGF Protein (#236-EG),
Recombinant Human TGF-a Protein (#293-A) were purchased from R&D Systems.
Mini-PROTEAN® TGX Precast Gels (10% polyacrylamide) (#456-1036), Clarity Western ECL
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reagents (#1705060) were purchased from Bio-Rad Laboratories, Inc.
Cell culture. CHO-K1 cells (ATCC) were cultured in F12K Medium supplemented with 10%
FBS and Pen-Strep (100 I.U./mL penicillin and 100 mg/mL streptomycin) at 37°C in a CO2/air
(5%/95%) incubator. Cells were transfected using the TransIT-CHO Transfection Kit (Mirus Bio
LLC) (CHO-K1), according to the manufacturer’s instructions. Cell densities for all mammalian
cell lines were determined with a Cellometer® Auto T4 automated counter. All cells were bona
fide lines and periodically tested for mycoplasma with DNA methods
Cloning and Mutagenesis. All EGFR DNA variants were cloned from a pcDNA3.1 plasmid,
generously donated by the Kuriyan Group (University of California, Berkeley), containing the
sequence of the full-length EGFR with an N-terminal FLAG tag [18,22]. Mutations were
introduced into the wild-type, CCH-1 and CCH-10 EGFR sequences using Quikchange
Lightning site-directed mutagenesis kit (Agilent Technologies)/ Gibson assembly (NEB) of
G-Blocks and linearized backbone fragments according to the manufacturer’s instructions, with
primers (purchased from Integrated DNA Technologies) listed in Table 4.1. All DNA variants
were ampliﬁed with XL-10 Gold Ultracompetent cells (Agilent Technologies).
Bipartite Tetracysteine Display Assay i.e. Surface ReAsH Labeling Studies and Total
Internal Resonance Fluorescence (TIRF) Microscopy. ReAsH labeling was accomplished as
described previously [21,17] by treating CHO-K1 cells expressing EGFR variants with an
endocytosis inhibition cocktail (10 mM NaN3, 2 mM NaF, 5 mM 2-deoxy-D-glucose in F12-K
media) for 1 hr at 37oC. Cells were stimulated without/with 100 ng/mL of EGF (16.7 nM)) and
TGF-α

(16.7

nM)

prior

to

labeling.

Cells

were

washed

once

with

endocytosis

inhibitor-containing media before incubation with ReAsH labeling solution (2 mM ReAsH
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(ThermoFisher Scientific), 20 mM BAL (Acros Organics) in F12K media) for 1 hr at 37oC. Cells
were washed and incubated with endocytosis inhibitor-containing F12K media supplemented
with 100 mM BAL for 10 min at 37oC. The media was removed, and cells ﬁxed using 4%
paraformaldehyde (PFA) in DPBS for 25 min at room temperature. Fixed cells were washed with
DPBS and blocked with 10% BSA in DPBS for 30 min at 37oC. Cells were then labeled with
primary antibody (mouse monoclonal mouse M2 anti-FLAG, 1:1000 dilution in 10% BSA in
DPBS) for 1 hr at 37oC, washed thrice with 10% BSA in DPBS, then incubated with secondary
antibody (AlexaFluor488-conjugated goat anti-mouse, 1:2000 dilution in 10% BSA in DPBS) for
1 hr at 37oC. Cells were then washed twice with 10% BSA in DPBS, washed once with DPBS,
then nuclear-stained with Hoescht 33342 (1.62 mM in DPBS) for 5 min at 37oC. Cells were then
washed once with DPBS and stored in DPBS at 4oC, prior to imaging. Labeled cells were
monitored via TIRF microscopy, conducted on a Leica microsystems AM TIRF MC DMI6000B
ﬁtted with an EM-CCD camera (Hamamatsu) with HCX PL APO 63x/1.47 oil corrective
objectives, as described previously[17,21]. Images were analyzed with ImageJ (FIJI) as
described previously[17,21].
Western Blot Analysis of EGFR Expression and Autophosphorylation. Western blot analysis
of EGFR expression and autophosphorylation in transfected CHO-K1 cells was accomplished
as described previously with slight modification [17,21]. CHO-K1 cells expressing FLAG-tagged
EGFR variants were serum starved overnight (~12 hours). 48 hr post seeding cells were
stimulated without/with 100 ng/mL of EGF (16.7 nM) or TGF-α (16.7 nM) for 5 min at 37oC,
washed with serum free F12K media, and lysed in 100 uL of lysis buffer (50 mM Tris,150 mM
NaCl, 1 mM EDTA, 1 mM NaF, 1% Triton X-100, pH 7.5, 1x cOmplete protease inhibitor
cocktail, 1x Phos-Stop) for 1 hr. Clariﬁed cell lysates were subjected to reducing 4-15%
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polyacrylamide SDS-PAGE electrophoresis and transferred to immuno-blot PVDF membranes.
Membranes were blocked with 5% milk in TBS-T Buffer (50 mM Tris, 150 mM NaCl, 0.1%
Tween, pH 7.4) for 1 hr followed by an overnight incubation at 4oC of indicated primary (rabbit
or mouse) antibodies. Blots were washed with TBS-T and incubated with either anti-rabbit or
anti-mouse goat horseradish peroxidase conjugate secondary antibodies for 1 hr at room
temperature, then washed with TBS-T. Blots were then visualized using Clarity Western ECL
reagents on a ChemiDoc XRS+/ ChemiDocMP instrument, and intensities of immuno-stained
bands measured with ImageJ 64[125]. When assessing phosphorylation of EGFR/ gel loading
at multiple positions using the same samples, the blots obtained with a given phospho-EGFR
antibody were stripped with Restore Western Blot Stripping Buffer/ and antibody stripping
buffer (Tris-HCl (62.5 mM), SDS (2%w/v), 2-mercaptoethanol (0.7%v/v)) and re-probed with a
different phospho-EGFR antibody.
Amplex red assay to detect peroxidase activity. Cellular lysates from CHO-K1 cells
expressing FLAg tagged variants were prepared as described for western blot analyses.
Clariﬁed cell lysates were quantified for total protein content using Pierce™ 660nm Protein
Assay Reagent according to the manufacturer’s instructions. 20ug of the clarified cellular lysate
from each sample was diluted in 100 uL of DPBS pH 7.4 and was set up in Corning 96-Well x
360µL clear flat bottom assay microplate, non-treated black polystyrene. A 2X reaction mixture
was prepared by mixing 25 uL of 10mM Amplex UltraRed stock (50 uM final conc.), 11.4 uL of
3% H2O2 (1mM final conc.) and 2.5 mL of DPBS pH 7.4. Using a multichannel pipette, 100 uL
of reaction mixture was added to a 100 uL cell lysate solution and the fluorescence at 530/590
nm ex/em was recorded at regular intervals of 5 min for 1 hour on a Synergy HTX microplate
plate reader.
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Table 4.1. List of mutagenesis primers/ G-blocks used for cloning in Chapter 4
S.No.

Name

Primer/ G-block sequence

Project 1: Investigating the role of multimerization on JM structure
1.

VEN/ERR forward 5'-gtggcactgtatgcactcagacctcctctcaaactcccttggctcaccct-3'
(V562E, E527R,
N528R)

2.

VEN/ERR reverse
(V562E, E527R,
N528R)

5'-agggtgagccaagggagtttgagaggaggtctgagtgcatacagtgccac-3'

3.

I562R forward

5'-ccagtgtgcccactacagggacggcccccac-3'

4.

I562R reverse

5'-gtgggggccgtccctgtagtgggcacactgg-3'

5.

V592E forward

5'-cacaggtggcactcatggccggcgt-3'

6.

V592E reverse

5'-acgccggccatgagtgccacctgtg-3'

7.

I545A forward

5'-cgtcctgtgcaggtggcgttcatggcctgagg-3'

8.

I545A reverse

5'-cctcaggccatgaacgccacctgcacaggacg-3'

9.

I556A forward

5'-gggcacactgggcacagttgtctggtccccgtcc-3'

10.

I556A reverse

5'-ggacggggaccagacaactgtgcccagtgtgccc-3'

11.

I545K forward

5'-cctgtgcaggtcttgttcatggcctgaggcag-3'

12.

I545K reverse

5'-ctgcctcaggccatgaacaagacctgcacagg-3'

13.

I556K forward

5'-tgggcacactgcttacagttgtctggtccccgt-3'

14.

I556K reverse

5'-acggggaccagacaactgtaagcagtgtgccca-3'

15.

T548R forward

5'-tccccgtcctctgcaggtgatgttcatgg-3'

16.

T548R reverse

5'-ccatgaacatcacctgcagaggacgggga-3'

17.

N554R forward

5'-gcacactggatacacctgtctggtccccgtcctg-3'

18.

N554R reverse

5'-caggacggggaccagacaggtgtatccagtgtgc-3'

19.

EGFR lin. forward

5’-GGCCTGAGGCAGGCACTCT-3’

20.

EGFR lin. reverse

5’-CTGTGCCATCCAAACTGCACC-3’
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21.

G-Block (AARE)
I545A/ I556A/
I562R/ V592E

5’-AGAGTGCCTGCCTCAGGCCatgaacgcaacctgcacaggacggggaccagac
aactgtgcacagtgtgcccactacagagacggcccccactgcgtcaagacctgcccggcag
gagtcatgggagaaaacaacaccctggtctggaagtacgcagacgccggccatgagtgcca
cCTGTGCCATCCAAACTGCACC-3’

22.

G-Block (KKRE)
I545K/ I556K/
I562R/ V592E

5’-AGAGTGCCTGCCTCAGGCCatgaacaagacctgcacaggacggggaccagac
aactgtaagcagtgtgcccactacagagacggcccccactgcgtcaagacctgcccggcag
gagtcatgggagaaaacaacaccctggtctggaagtacgcagacgccggccatgagtgcca
cCTGTGCCATCCAAACTGCACC-3’

23.

G-Block (RR)
(T548R, N554R)

5’-AGAGTGCCTGCCTCAGGCCatgaacatcacctgcagaggacggggaccagac
agatgtatccagtgtgcccactacattgacggcccccactgcgtcaagacctgcccggcagg
agtcatgggagaaaacaacaccctggtctggaagtacgcagacgccggccatgtgtgccac
CTGTGCCATCCAAACTGCACC-3’

Project 2: Evaluating the interactome of EGFR using APEX2 proximity labeling and MS
1.

APEX2 lin. fwd

5’-ATGTATATCTCCTTCTTAAAGTTAAACAAAATTATT-3’

2.

APEX2 lin. revs

5’-taacaaagcccgaaaggaag-3’

3.

EGFR lin. fwd

5’-GTCTAGAGGGCCCGTTTAAACCCG-3’

4.

EGFR lin. revs

5’-GCTCCAATAAATTCACTGCTTTGTGGCG-3’

5.

EGFR-APEX2
forward

5’-GCGCCACAAAGCAGTGAATTTATTGGAGCAGGCTCGGGCgg
aaagtcttacccaactgtgagtgctgat-3'

6.

EGFR-APEX2
reverse

5’-TGATCAGCGGGTTTAAACGGGCCCTCTAGACTAggcatcagcaa
acccaagctcggaaagctt-3’

7.

D208N-APEX2 (f)

5’-CTTCAGCTACCTTCTaacAAGGCTCTTTTGTC-3’

8.

D208N-APEX2 (r)

5’-GACAAAAGAGCCTTgttAGAAGGTAGCTGAAG-3’

9.

G628A-EGFR (f)

5’-ACTGGGATGGTGgccGCCCTCCTCTTG-3’

10.

G628A-EGFR (r)

5’-CAAGAGGAGGGCggcCACCATCCCAGT-3’

11.

G628F-EGFR (f)

5’-GCCACTGGGATGGTGttcGCCCTCCTCTTGCTG-3’

12.

G628F-EGFR (r)

5’-CAGCAAGAGGAGGGCgaaCACCATCCCAGTGGC-3’

13.

G628V-EGFR (f)

5’-ACTGGGATGGTGgtgGCCCTCCTCTTG-3’

14.

G628V-EGFR (r)

5’-CAAGAGGAGGGCcacCACCATCCCAGT-3’

15.

K721M-EGFR (f)

5’-GTTAAAATTCCCGTCGCTATCgctGAATTAAGA-3’

16.

K721M-EGFR (r)

5’-CTCTTAATTCagcGATAGCGACGGGAATTTTAAC-3’
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Figure 4.1. Inhibiting EGFR multimerization does not affect the EGF-type JM-A coiled coil
structure (A) Representative TIRF-M images of CHO-K1 cells illustrating ReAsH labeling (red
fluorescence) and expression (green fluorescence) of FLAG-tagged CCH-1 variants of WT
EGFR, IIIV/AARE, IIIV/KKRE, VEN/ERR, TN/RR in the absence and presence of EGF or TGF-α
stimulation (16.7 nM). Scale bars represent 10 µm. (B) Bar Plots illustrating the quantification of
TIRF-M results from ‘n’ cells as a fold-increase in expression-corrected ReAsH fluorescence
over background. Error bars represent s.e.m., ****p<0.0001, ***p<0.001, from one-way ANOVA
with Dunnett’s post-analysis accounting comparison to the control for each case without
growth factor treatment. n.s., not significant. (C) Representative western blots illustrating
expression (FLAG) and extent of Y1173, Y1068 and Erk phosphorylation of FLAG-tagged
CCH-1 variants of WT EGFR, IIIV/AARE, IIIV/KKRE, VEN/ERR, TN/RR in the absence and
presence of EGF or TGF-α stimulation (16.7 nM). Tubulin was used as a loading control.
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Figure 4.2. Mechanism of coiled coil mediated control of EGFR biology and methods to
dissect the EGFR interactome. The alternate JM-A coiled coil structures can regulate EGFR
biology by two possible mechanisms. (A) The two JM-A structures can alter the JM-A surface
that interacts with the EGFR kinase thereby altering kinase positioning and activity thereby
affecting the recruitment of diverse intracellular adaptors and down regulatory proteins. (B)
Alternately the two JM-A surface can directly alter the interactome of EGFR. (C) The coiled coil
dependent interactome of EGFR can be dissected using proximity labeling methodology
(utilizing the engineered peroxidase APEX2) followed by identification and characterization with
mass spectrometry.
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Figure 4.3. EGFR-APEX2 fusion retains enzymatic activity in both EGFR and APEX2 parts.
(A) Domain diagram of FLAG-tagged EGFR/ APEX constructs illustrating sequences of
EGFR-APEX2, WT EGFR, K721M-EGFR (whose EGFR kinase activity is abrogated), APEX2 and
D208N-APEX2 (whose peroxidase activity is abrogated). EGFR is fused to APEX2 with a short
flexible GGS linker. Location of K721M or D208N mutations is indicated in the domain diagram
with a yellow oval. (B) Representative western blot illustrating the expression of FLAG-tagged
APEX2, EGFR-APEX2 and D208N-APEX2 as detected with an anti-FLAG antibody. Tubulin was
used as a loading control. Representative western blots illustrating the expression (FLAG) and
autophosphorylation activity of WT EGFR, EGFR-APEX2 and K721M-EGFR (negative control)
at C-tail tyrosine residues (C) Y1045 and (D) Y1068. Tubulin was used as a loading control. Bar
plots illustrating the normalized percent of (E) pY1045/ FLAG or (F) pY1068/ FLAG for western
blots shown in (C) or (D) respectively. In each case, pY-EGFR/ FLAG signal is normalized to the
signal for WT EGFR treated with EGF. Error bars represent S.E.M. ****p<0.0001, ***p<0.001,
from one-way ANOVA with Dunnett’s post-analysis accounting comparison to no growth factor
treated control for each mutant case (black symbols) and comparison among variants to WT
EGFR treated with EGF (orange symbols) or WT EGFR treated with TGF-ɑ (yellow symbols)
n.s., not significant. (G) Reaction schematic illustrating the peroxidase (APEX2) mediated
conversion of Amplex Red (non-fluorescent) to Resorufin (fluorescent) in the presence of
hydrogen peroxide. (H) Results of amplex red assay illustrating the time dependent change in
fluorescence intensity detected from reaction of Amplex Red and H2O2 with cellular lysate from
CHO-K1 cells expressing APEX2 (pink), EGFR-APEX2 (without/ with 16.7 nM EGF /TGF-ɑ
treatment; represented by grey, orange and yellow lines respectively), D208N-APEX2 (purple;
negative control).
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